Ericdao的个人主页 - 老虎社区

Ericdao

Ericdao

暂无个人介绍

IP属地：未知

397关注

14粉丝

0主题

0勋章

2022-01-22

Cathy will be gone soon

‘Anti-ARKK’ ETF Amasses $234 Million as Cathie Wood Struggles

2022-01-17

Nice

Moderna: High Upside Potential At Current Prices

2021-12-24

It's always the up and down

S&P 500 hits record close as Omicron fears ebb

2021-12-21

Should start positioning at 86. 70 is too bearish

Let the Roblox Share Price Decline to $70, Then Start a Position

2021-12-18

Semicon industry nvr die

Wedbush's Dan Ives: Don't throw in the towel on tech

2021-11-26

Will it ? Well market is insane, anything can happen [开心] [开心]

Will Palantir Be a Trillion-Dollar Stock by 2040?

2021-11-07

Over aggressive expansion, Convid killed him

Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China

2021-10-18

Buy. No regrets

Fauci Says U.S. to Consider Mix-and-Match Boosters for Covid-19

2021-10-17

GOOD PICK

5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025

2021-10-15

Too high already, time for it to cool down

抱歉，原内容已删除

2021-10-13

Buy

BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?

2021-10-06

Still a falling knife

抱歉，原内容已删除

2021-10-06

Dead cat rebound

抱歉，原内容已删除

2021-10-04

Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful

3 Stocks That Can Double Again in the Fourth Quarter

2021-10-04

V good recommendations. I will include visa also

抱歉，原内容已删除

2021-10-02

Will report at the hell. Not worth trading [开心]

抱歉，原内容已删除

2021-09-10

See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped

抱歉，原内容已删除

2021-09-09

$GameStop(GME)$Aviod, more downside to come.

2021-09-08

She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.

Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire

2021-09-05

This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574662162410712","uuid":"3574662162410712","gmtCreate":1611568139053,"gmtModify":1628390403937,"name":"Ericdao","pinyin":"ericdao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":397,"tweetSize":26,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":630619131,"gmtCreate":1642812029157,"gmtModify":1642812029359,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Cathy will be gone soon&nbsp;","listText":"Cathy will be gone soon&nbsp;","text":"Cathy will be gone soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/630619131","repostId":"1116834406","repostType":4,"repost":{"id":"1116834406","pubTimestamp":1642783251,"share":"https://www.laohu8.com/m/news/1116834406?lang=&edition=full","pubTime":"2022-01-22 00:40","market":"us","language":"en","title":"‘Anti-ARKK’ ETF Amasses $234 Million as Cathie Wood Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=1116834406","media":"Bloomberg","summary":"Tuttle’s SARK is up by about 50% since its November launchARKK has tumbled as rising yields dent hig","content":"<html><head></head><body><ul><li>Tuttle’s SARK is up by about 50% since its November launch</li><li>ARKK has tumbled as rising yields dent high-growth stocks</li></ul><p>A controversial ETF with a singular mission to exploit weakness in Cathie Wood’s flagship fund has now amassed $234 million in assets as the new year rout in richly priced tech stocks deepens.</p><p>After a low-key start, the Tuttle Capital Short Innovation ETF (ticker SARK) now boasts an impressive haul for a fund less than three months old after soaring about 50% since inception, according to data compiled by Bloomberg.</p><p>Thank the bond-spurred exodus from high-growth companies with questionable profit outlooks famously beloved by Wood and her firm, ARK Investment Management.</p><p>SARK seeks to win when the ARK Innovation ETF (ARKK) loses, using swap contracts to short the fund. The Tuttle product has won a slew of fans in the tech wreck, posting positive inflows for 10 trading days running.</p><p>While inverse funds are common enough in the $6.9 trillion U.S. ETF industry, SARK stands out for its focus on a single manager.</p><p>Its low-profile but sustained rally suggests more traders are finally prepared to bet against Wood. Even as ARKK’s famed outperformance against the S&amp;P 500 evaporates, investors have proved intensely loyal with modest outflows.</p><p><img src=\"https://static.tigerbbs.com/0793e5394612f3fbda4269aba6df0f92\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"/></p><p>“I’m honestly not surprised at it just taking in money,” said James Seyffart, Bloomberg Intelligence ETF analyst. “The trend is your friend and for ARK right now the trend is still negative.”</p><p>The jump in Treasury yields and an expectation of tighter monetary policy have weighed on many of the stocks favored by Wood and ARK. ARKK plunged 20% this year through Thursday, while SARK was up 22%.</p><p>Matthew Tuttle, chief executive officer of Tuttle Capital Management LLC, noted that SARK has recently been notching inflows even on days when ARKK climbs. To Tuttle, it’s a sign investors increasingly see the fund as a hedging tool or a wager on the macro environment -- not just a way to capitalize on the downward momentum of speculative equities touted by Wood and her team.</p><p>“I do think inflows can continue, regardless of how ARKK does from here,” he said by email.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>‘Anti-ARKK’ ETF Amasses $234 Million as Cathie Wood Struggles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n‘Anti-ARKK’ ETF Amasses $234 Million as Cathie Wood Struggles\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-22 00:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-21/-anti-arkk-etf-amasses-234-million-as-cathie-wood-struggles?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tuttle’s SARK is up by about 50% since its November launchARKK has tumbled as rising yields dent high-growth stocksA controversial ETF with a singular mission to exploit weakness in Cathie Wood’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-21/-anti-arkk-etf-amasses-234-million-as-cathie-wood-struggles?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2022-01-21/-anti-arkk-etf-amasses-234-million-as-cathie-wood-struggles?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116834406","content_text":"Tuttle’s SARK is up by about 50% since its November launchARKK has tumbled as rising yields dent high-growth stocksA controversial ETF with a singular mission to exploit weakness in Cathie Wood’s flagship fund has now amassed $234 million in assets as the new year rout in richly priced tech stocks deepens.After a low-key start, the Tuttle Capital Short Innovation ETF (ticker SARK) now boasts an impressive haul for a fund less than three months old after soaring about 50% since inception, according to data compiled by Bloomberg.Thank the bond-spurred exodus from high-growth companies with questionable profit outlooks famously beloved by Wood and her firm, ARK Investment Management.SARK seeks to win when the ARK Innovation ETF (ARKK) loses, using swap contracts to short the fund. The Tuttle product has won a slew of fans in the tech wreck, posting positive inflows for 10 trading days running.While inverse funds are common enough in the $6.9 trillion U.S. ETF industry, SARK stands out for its focus on a single manager.Its low-profile but sustained rally suggests more traders are finally prepared to bet against Wood. Even as ARKK’s famed outperformance against the S&P 500 evaporates, investors have proved intensely loyal with modest outflows.“I’m honestly not surprised at it just taking in money,” said James Seyffart, Bloomberg Intelligence ETF analyst. “The trend is your friend and for ARK right now the trend is still negative.”The jump in Treasury yields and an expectation of tighter monetary policy have weighed on many of the stocks favored by Wood and ARK. ARKK plunged 20% this year through Thursday, while SARK was up 22%.Matthew Tuttle, chief executive officer of Tuttle Capital Management LLC, noted that SARK has recently been notching inflows even on days when ARKK climbs. To Tuttle, it’s a sign investors increasingly see the fund as a hedging tool or a wager on the macro environment -- not just a way to capitalize on the downward momentum of speculative equities touted by Wood and her team.“I do think inflows can continue, regardless of how ARKK does from here,” he said by email.","news_type":1},"isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697840047,"gmtCreate":1642415216001,"gmtModify":1642415216206,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697840047","repostId":"1131862461","repostType":4,"repost":{"id":"1131862461","pubTimestamp":1642412568,"share":"https://www.laohu8.com/m/news/1131862461?lang=&edition=full","pubTime":"2022-01-17 17:42","market":"us","language":"en","title":"Moderna: High Upside Potential At Current Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862461","media":"Seeking Alpha","summary":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p>Advantages of mRNA Technology</p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><blockquote>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.</blockquote><blockquote>Source:Millapore Sigma</blockquote><p>There are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><b>COVID-19 Progress</b></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul><p>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><blockquote>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.</blockquote><blockquote>Source: Steven Kelly, President and Chief Executive Officer of Carisma</blockquote><p>Right now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><b>Manufacturing Capacity</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><b>Risks</b></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><b>Analyst Price Targets</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><b>Valuation</b></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><b>Conclusion</b></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: High Upside Potential At Current Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: High Upside Potential At Current Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 17:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported ...</p>\n\n<a href=\"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862461","content_text":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.Maddie Meyer/Getty Images NewsModerna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world's most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna's first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna's mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna's stock today.Advantages of mRNA TechnologyThe reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.The development and manufacturing of mRNA for use as therapeuticsandvaccines are comparatively simple, scalableandextremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people's arms. Eventually, this response time could shrink to matter of a few months.Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.COVID-19 ProgressCOVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:11 deaths per 100,000: Sinovac7.8 deaths per 100,000: Sinopharm6.2 deaths per 100,000: Pfizer/BioNTech1 death per 100,000: ModernaOver the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna's COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.Because of the huge demand for Moderna's vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.Moderna Spikevax advanced purchase agreementsBecause COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (\"APA\") and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of '22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.How COVID-19 is likely to evolveCurrently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna's post pandemic plan to replace the likely COVID-19 vaccine declining revenues?Moderna's Plan Moving ForwardModerna Product Strategy in 2022The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.Moderna vision for pan-respiratory vaccineModerna's vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn't be surprised if a pan-respiratory vaccine starts to appear within two years.Moderna Strategy After COVID-19Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax's pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax's pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna's most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics' engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won't go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics' CAR-Macrophage's technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.Moderna's deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients' own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.Moderna capital allocation prioritiesModerna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna's number one capital allocation priority is investing in R&D, manufacturing infrastructure and continuing to build out the company's commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.Manufacturing CapacityModerna In-country vaccine manufacturingThere is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.RisksThe major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna's stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna's stock much lower.Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.Analyst Price TargetsModerna Analyst Price TargetsThe above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.ValuationData by YChartsData by YChartsData by YChartsThe comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna's current valuation will be viewed in hindsight as being way too low. If most of Moderna's pipeline fails then the valuation will be viewed in hindsight as being way too high.ConclusionModerna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna's stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.","news_type":1},"isVote":1,"tweetType":1,"viewCount":533,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698891874,"gmtCreate":1640331386141,"gmtModify":1640331634599,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"It's always the up and down&nbsp;","listText":"It's always the up and down&nbsp;","text":"It's always the up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698891874","repostId":"2193078140","repostType":4,"repost":{"id":"2193078140","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299360,"share":"https://www.laohu8.com/m/news/2193078140?lang=&edition=full","pubTime":"2021-12-24 06:42","market":"us","language":"en","title":"S&P 500 hits record close as Omicron fears ebb","url":"https://stock-news.laohu8.com/highlight/detail?id=2193078140","media":"Reuters","summary":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* ","content":"<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 hits record close as Omicron fears ebb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 hits record close as Omicron fears ebb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193078140","content_text":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* Weekly jobless claims unchanged at 205,000\n* Consumer spending increases 0.6% in November\n* Indexes up: Dow 0.55%, S&P 0.62%, Nasdaq 0.85%\nDec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.\nStocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&P 500 sectors, led by consumer discretionary and industrials, which both rose about 1.2%.\nVaccine makers AstraZeneca Plc and Novavax Inc said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.\nThe arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.\n“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\nThe Dow Jones Industrial Average rose 196.67 points, or 0.55%, to 35,950.56, the S&P 500 gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite added 131.48 points, or 0.85%, to 15,653.37.\nDefensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector fell 0.4%.\nThe S&P 500 has gained for three days, after falling in the three prior sessions.\n“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.\nFor the week, the S&P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.\nTrading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.\nIn another medical development against the pandemic, the United States authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.\nThe number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.\nTesla Inc shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.\nThe S&P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.\nThe S&P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.\nAbout 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693469990,"gmtCreate":1640063725361,"gmtModify":1640064058108,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Should start positioning at 86. 70 is too bearish&nbsp;","listText":"Should start positioning at 86. 70 is too bearish&nbsp;","text":"Should start positioning at 86. 70 is too bearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693469990","repostId":"1180317442","repostType":4,"repost":{"id":"1180317442","pubTimestamp":1640057402,"share":"https://www.laohu8.com/m/news/1180317442?lang=&edition=full","pubTime":"2021-12-21 11:30","market":"us","language":"en","title":"Let the Roblox Share Price Decline to $70, Then Start a Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1180317442","media":"InvestorPlace","summary":"After a meteoric rise, hot metaverse bet RBLX stock just needs to cool down","content":"<p>California-based online entertainment platform&nbsp;<b>Roblox</b>&nbsp;(NYSE:<b><u>RBLX</u></b>) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the red-hot metaverse space, RBLX stock has generated major buzz on Wall Street.</p>\n<p>Indeed, as the term “metaverse” gained traction in the financial news headlines, Roblox share price soared. However, as the old saying goes, trees don’t grow straight to the heavens.</p>\n<p>In other words, even white-hot RBLX stock couldn’t just keep going up forever. All it took was a worse-than-expected user-growth update, and Roblox was suddenly out of favor with investors.</p>\n<p>It’s funny how the tide of sentiment can turn so quickly. Contrarians who still believe in the future of metaverse-anchored gaming can take advantage of the market’s overreaction as Roblox’s news has not been all bad.</p>\n<p><b>A Closer Look at RBLX Stock</b></p>\n<p>Just to recap, RBLX stock&nbsp;debuted on March 10&nbsp;of this year. Interestingly enough, the shares became publicly traded through the&nbsp;very first direct listing of 2021.</p>\n<p>The stock actually began trading at $64.50 and finished its first day of trading at $69.50. Then its upward momentum accelerated as its price ramped up to a 52-week high of $141.60 in November.</p>\n<p>Unfortunately, this moon shot wasn’t sustainable. RBLX stock fell quickly in November’s back half and continued declining in December, falling as low as $95 and change.</p>\n<p>Experts often recommend avoiding buying sharply falling stocks in order to refrain from “catching a falling knife.”</p>\n<p>Roblox has fairly solid support at $70, so it’s not a terrible idea to be patient and let its share price hit that critical price point before taking a position in the name.</p>\n<p><b>A Subtle Bug</b></p>\n<p>Some may assume that RBLX stock simply fell victim to gravity after flying too far, too fast.</p>\n<p>Yet this wasn’t just an instance of Icarus flying too close to the sun. Rather, there were specific incidents that popped the shares’ bubble.</p>\n<p>The first of these incidents took place in late October and early November, when Roblox reportedly experienced a three-day&nbsp;outage during the Halloween weekend.</p>\n<p>This was a period in which the company would typically take in at least $15 million in revenue. So&nbsp; that three-day outage was a big deal for Roblox. Just as painfully, RBLX stock lost more than $1.5 billion worth of its market capitalization as a result of this incident.</p>\n<p>Of course, Roblox CEO David Baszucki had some ” ‘splaining” to do. He claimed that the outage had been “especially difficult” as it involved a “combination of several factors.”</p>\n<p>“A core system in our infrastructure became overwhelmed, prompted by a subtle bug in our backend service communications while under heavy load… This was not due to any peak in external traffic or any particular experience,” Baszucki explained.</p>\n<p><b>A Possible Overreaction</b></p>\n<p>Evidently, Roblox’s investors weren’t too impressed with the CEO’s account or at least Baszucki’s explanation didn’t prevent many investors from unloading all of their RBLX stock.</p>\n<p>Fast-forward to mid-December, and Roblox released its&nbsp;usage statistics&nbsp;for the month of November. Investors reacted very negatively to the data, and they may have overreacted.</p>\n<p>Roblox counted 49.4 million average daily active users in November, up 35% year-over-year. That sounds pretty good, if you ask me.</p>\n<p>On the other hand, that figure was less than the 50.5 million average daily active users Roblox reported for the first 27 days of October.</p>\n<p>That’s not a huge decline. And in November, Roblox generated estimated bookings of between $208 million and $211 million, up 22% to 24% YOY.</p>\n<p>On top of all that, Roblox reported 3.6 billion hours engaged in November, representing a 32% YOY gain.</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s not always easy to tread the line between optimism and caution.</p>\n<p>Yet that’s the right approach to RBLX stock, given the investing community’s negative sentiment towards Roblox at the moment. Thus, it’s wise to let the share price continue on its likely path to $70 and then re-evaluate and take a long position in the name if you’re ready to do so.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Let the Roblox Share Price Decline to $70, Then Start a Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLet the Roblox Share Price Decline to $70, Then Start a Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>California-based online entertainment platform Roblox (NYSE:RBLX) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the ...</p>\n\n<a href=\"https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180317442","content_text":"California-based online entertainment platform Roblox (NYSE:RBLX) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the red-hot metaverse space, RBLX stock has generated major buzz on Wall Street.\nIndeed, as the term “metaverse” gained traction in the financial news headlines, Roblox share price soared. However, as the old saying goes, trees don’t grow straight to the heavens.\nIn other words, even white-hot RBLX stock couldn’t just keep going up forever. All it took was a worse-than-expected user-growth update, and Roblox was suddenly out of favor with investors.\nIt’s funny how the tide of sentiment can turn so quickly. Contrarians who still believe in the future of metaverse-anchored gaming can take advantage of the market’s overreaction as Roblox’s news has not been all bad.\nA Closer Look at RBLX Stock\nJust to recap, RBLX stock debuted on March 10 of this year. Interestingly enough, the shares became publicly traded through the very first direct listing of 2021.\nThe stock actually began trading at $64.50 and finished its first day of trading at $69.50. Then its upward momentum accelerated as its price ramped up to a 52-week high of $141.60 in November.\nUnfortunately, this moon shot wasn’t sustainable. RBLX stock fell quickly in November’s back half and continued declining in December, falling as low as $95 and change.\nExperts often recommend avoiding buying sharply falling stocks in order to refrain from “catching a falling knife.”\nRoblox has fairly solid support at $70, so it’s not a terrible idea to be patient and let its share price hit that critical price point before taking a position in the name.\nA Subtle Bug\nSome may assume that RBLX stock simply fell victim to gravity after flying too far, too fast.\nYet this wasn’t just an instance of Icarus flying too close to the sun. Rather, there were specific incidents that popped the shares’ bubble.\nThe first of these incidents took place in late October and early November, when Roblox reportedly experienced a three-day outage during the Halloween weekend.\nThis was a period in which the company would typically take in at least $15 million in revenue. So  that three-day outage was a big deal for Roblox. Just as painfully, RBLX stock lost more than $1.5 billion worth of its market capitalization as a result of this incident.\nOf course, Roblox CEO David Baszucki had some ” ‘splaining” to do. He claimed that the outage had been “especially difficult” as it involved a “combination of several factors.”\n“A core system in our infrastructure became overwhelmed, prompted by a subtle bug in our backend service communications while under heavy load… This was not due to any peak in external traffic or any particular experience,” Baszucki explained.\nA Possible Overreaction\nEvidently, Roblox’s investors weren’t too impressed with the CEO’s account or at least Baszucki’s explanation didn’t prevent many investors from unloading all of their RBLX stock.\nFast-forward to mid-December, and Roblox released its usage statistics for the month of November. Investors reacted very negatively to the data, and they may have overreacted.\nRoblox counted 49.4 million average daily active users in November, up 35% year-over-year. That sounds pretty good, if you ask me.\nOn the other hand, that figure was less than the 50.5 million average daily active users Roblox reported for the first 27 days of October.\nThat’s not a huge decline. And in November, Roblox generated estimated bookings of between $208 million and $211 million, up 22% to 24% YOY.\nOn top of all that, Roblox reported 3.6 billion hours engaged in November, representing a 32% YOY gain.\nThe Bottom Line\nIt’s not always easy to tread the line between optimism and caution.\nYet that’s the right approach to RBLX stock, given the investing community’s negative sentiment towards Roblox at the moment. Thus, it’s wise to let the share price continue on its likely path to $70 and then re-evaluate and take a long position in the name if you’re ready to do so.","news_type":1},"isVote":1,"tweetType":1,"viewCount":809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","pubTimestamp":1639806035,"share":"https://www.laohu8.com/m/news/1161245886?lang=&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p>\n<p>\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p>\n<p>Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p>\n<p>\"This is an opportunity, not the start of a downtrend for tech,\" he said.</p>\n<p>Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p>\n<p>He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p>\n<p>That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p>\n<p>\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p>\n<p>Rather, Ives suggested investors \"double down on their winners.\"</p>\n<p>Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p>\n<p>The main laggard in the group is CYBR, which is basically flat on the year:</p>\n<p><img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 13:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"...</p>\n\n<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1},"isVote":1,"tweetType":1,"viewCount":1061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"repost":{"id":"2186916023","pubTimestamp":1637848500,"share":"https://www.laohu8.com/m/news/2186916023?lang=&edition=full","pubTime":"2021-11-25 21:55","market":"us","language":"en","title":"Will Palantir Be a Trillion-Dollar Stock by 2040?","url":"https://stock-news.laohu8.com/highlight/detail?id=2186916023","media":"Motley Fool","summary":"The data-mining firm has a slim chance of eventually joining the 12-zero club.","content":"<p><b>Palantir Technologies</b> (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.</p>\n<p>The bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.</p>\n<p>Palantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.</p>\n<p>Today, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.</p>\n<p>But let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.</p>\n<h2>How fast is Palantir growing?</h2>\n<p>Palantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.</p>\n<p>The company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.</p>\n<h2>Palantir's path toward a trillion-dollar market cap</h2>\n<p>Palantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like <b><a href=\"https://laohu8.com/S/CRM\">Salesforce</a> </b>(NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.</p>\n<p>If it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.</p>\n<p>If Palantir's revenue growth then slows down to 15% per year, which would be more comparable to <b>Microsoft</b>'s (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.</p>\n<p>Assuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.</p>\n<p>Microsoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.</p>\n<p>Therefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.</p>\n<h2>Look beyond the market caps</h2>\n<p>Instead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.</p>\n<p>The company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.</p>\n<p>Palantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like <b>C3.ai</b>, <b>Salesforce</b>'s Tableau, and Glue from <b>Amazon</b> Web Services.</p>\n<p>The company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.</p>\n<h2>Is Palantir's stock still worth buying?</h2>\n<p>I still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Palantir Be a Trillion-Dollar Stock by 2040?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Palantir Be a Trillion-Dollar Stock by 2040?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 21:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186916023","content_text":"Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.\nThe bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.\nPalantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.\nToday, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.\nBut let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.\nHow fast is Palantir growing?\nPalantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.\nThe company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.\nPalantir's path toward a trillion-dollar market cap\nPalantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like Salesforce (NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.\nIf it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.\nIf Palantir's revenue growth then slows down to 15% per year, which would be more comparable to Microsoft's (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.\nAssuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.\nMicrosoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.\nTherefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.\nLook beyond the market caps\nInstead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.\nThe company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.\nPalantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like C3.ai, Salesforce's Tableau, and Glue from Amazon Web Services.\nThe company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.\nIs Palantir's stock still worth buying?\nI still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.","news_type":1},"isVote":1,"tweetType":1,"viewCount":798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842783902,"gmtCreate":1636244599834,"gmtModify":1636249290606,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Over aggressive expansion, Convid killed him&nbsp;","listText":"Over aggressive expansion, Convid killed him&nbsp;","text":"Over aggressive expansion, Convid killed him","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842783902","repostId":"2181744416","repostType":4,"repost":{"id":"2181744416","pubTimestamp":1636161660,"share":"https://www.laohu8.com/m/news/2181744416?lang=&edition=full","pubTime":"2021-11-06 09:21","market":"hk","language":"en","title":"Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2181744416","media":"钛媒体","summary":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has ann","content":"<p>BEIJING, November 5 (TMTPOST) — <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.</p>\n<p>Haidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.</p>\n<p><img src=\"https://static.tigerbbs.com/35715cef35710a06dc52a2418de4d934\" tg-width=\"1400\" tg-height=\"849\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Haidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.</p>\n<p>Haidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.</p>\n<p>“I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”</p>\n<p>Haidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p>","source":"taimeiti","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPopular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 09:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tmtpost.com/5842325.html?rss=qcloud><strong>钛媒体</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue ...</p>\n\n<a href=\"https://www.tmtpost.com/5842325.html?rss=qcloud\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.tmtpost.com/5842325.html?rss=qcloud","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181744416","content_text":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.\nHaidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.\n\nHaidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.\nHaidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.\n“I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”\nHaidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at one point.","news_type":1},"isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827789810,"gmtCreate":1634523506698,"gmtModify":1634523506960,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Buy. No regrets&nbsp;","listText":"Buy. No regrets&nbsp;","text":"Buy. No regrets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827789810","repostId":"1195761146","repostType":4,"repost":{"id":"1195761146","pubTimestamp":1634519374,"share":"https://www.laohu8.com/m/news/1195761146?lang=&edition=full","pubTime":"2021-10-18 09:09","market":"us","language":"en","title":"Fauci Says U.S. to Consider Mix-and-Match Boosters for Covid-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1195761146","media":"Bloomberg","summary":"Says immune response with J&J dose lower than mRNA vaccines\nVaccinated people can safely enjoy holid","content":"<ul>\n <li>Says immune response with J&amp;J dose lower than mRNA vaccines</li>\n <li>Vaccinated people can safely enjoy holiday season, Fauci says</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f0d7603ed41e1a74979fafb345fcc8a4\" tg-width=\"1400\" tg-height=\"933\" width=\"100%\" height=\"auto\"><span>A so-called mix-and-match booster for people who got the one-dose Johnson &amp; Johnson vaccine has been discussed among scientists and government experts. Photographer: Saul Martinez/Bloomberg</span></p>\n<p>President Joe Biden’s chief medical adviser said he expects U.S. regulators to consider whether people who got the one-dose Johnson &amp; Johnson vaccine should get an mRNA shot against Covid-19 as a booster.</p>\n<p>“If you boost people who have originally received&nbsp;J&amp;J&nbsp;with either&nbsp;Moderna&nbsp;or&nbsp;Pfizer, the level of antibodies that you induce in them is much higher than if you boost them with the original J&amp;J,” Anthony Fauci said on ABC’s “This Week” on Sunday.</p>\n<p>“But the data of boosting the J&amp;J first dose with a J&amp;J second dose is based on clinical data,” he said. “So what’s going to happen is that the FDA is going to look at all those data, look at the comparison, and make a determination of what they will authorize.”</p>\n<p>A so-called mix-and-match booster has been discussed among scientists and government experts, though no timeline has been released for when it might be officially considered. The issue is complicated by safety, supply and concern about confusing public messaging.</p>\n<p>Food and Drug Administration experts&nbsp;recommended&nbsp;a second Johnson &amp; Johnson shot for people 18 and older last week. They also&nbsp;backed&nbsp;a third dose of the Moderna Inc. shot -- which unlike J&amp;J uses mRNA technology -- for people at high risk of contracting Covid-19. The recommendations require backing by the FDA and the Centers for Disease Control and Prevention, which could come as soon as this week.</p>\n<p>The Pfizer Inc.-BioNTech SE vaccine, also based on mRNA technology, was cleared for boosters in September. More than 10 million third shots have been given in the U.S.</p>\n<p><b>Holiday Season</b></p>\n<p>Fauci said the individual choice of which booster to get would depend on several factors, including the&nbsp;risk of myocarditis, a heart inflammation that some evidence suggests is a risk for young men who get mRNA vaccines.</p>\n<p>“I believe there’s going to be a degree of flexibility of what a person who got the J&amp;J originally can do, either with J&amp;J or with the mix-and-match from other products,” Fauci said on “Fox News Sunday.”</p>\n<p>Fauci also said that people could safely enjoy gathering during the U.S. holiday season if vaccinated -- a message to some 66 million eligible people in the country who haven’t been inoculated.</p>\n<p>“When you do that, there’s no reason at all why you can’t enjoy the holidays in a family way, the way we’ve traditionally done it all along,” he said on “This Week.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fauci Says U.S. to Consider Mix-and-Match Boosters for Covid-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFauci Says U.S. to Consider Mix-and-Match Boosters for Covid-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-18 09:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-17/fauci-says-mix-and-match-booster-shots-will-be-considered?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Says immune response with J&J dose lower than mRNA vaccines\nVaccinated people can safely enjoy holiday season, Fauci says\n\nA so-called mix-and-match booster for people who got the one-dose Johnson & ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-17/fauci-says-mix-and-match-booster-shots-will-be-considered?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","JNJ":"强生","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-17/fauci-says-mix-and-match-booster-shots-will-be-considered?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195761146","content_text":"Says immune response with J&J dose lower than mRNA vaccines\nVaccinated people can safely enjoy holiday season, Fauci says\n\nA so-called mix-and-match booster for people who got the one-dose Johnson & Johnson vaccine has been discussed among scientists and government experts. Photographer: Saul Martinez/Bloomberg\nPresident Joe Biden’s chief medical adviser said he expects U.S. regulators to consider whether people who got the one-dose Johnson & Johnson vaccine should get an mRNA shot against Covid-19 as a booster.\n“If you boost people who have originally received J&J with either Moderna or Pfizer, the level of antibodies that you induce in them is much higher than if you boost them with the original J&J,” Anthony Fauci said on ABC’s “This Week” on Sunday.\n“But the data of boosting the J&J first dose with a J&J second dose is based on clinical data,” he said. “So what’s going to happen is that the FDA is going to look at all those data, look at the comparison, and make a determination of what they will authorize.”\nA so-called mix-and-match booster has been discussed among scientists and government experts, though no timeline has been released for when it might be officially considered. The issue is complicated by safety, supply and concern about confusing public messaging.\nFood and Drug Administration experts recommended a second Johnson & Johnson shot for people 18 and older last week. They also backed a third dose of the Moderna Inc. shot -- which unlike J&J uses mRNA technology -- for people at high risk of contracting Covid-19. The recommendations require backing by the FDA and the Centers for Disease Control and Prevention, which could come as soon as this week.\nThe Pfizer Inc.-BioNTech SE vaccine, also based on mRNA technology, was cleared for boosters in September. More than 10 million third shots have been given in the U.S.\nHoliday Season\nFauci said the individual choice of which booster to get would depend on several factors, including the risk of myocarditis, a heart inflammation that some evidence suggests is a risk for young men who get mRNA vaccines.\n“I believe there’s going to be a degree of flexibility of what a person who got the J&J originally can do, either with J&J or with the mix-and-match from other products,” Fauci said on “Fox News Sunday.”\nFauci also said that people could safely enjoy gathering during the U.S. holiday season if vaccinated -- a message to some 66 million eligible people in the country who haven’t been inoculated.\n“When you do that, there’s no reason at all why you can’t enjoy the holidays in a family way, the way we’ve traditionally done it all along,” he said on “This Week.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"repost":{"id":"2175112192","pubTimestamp":1634312035,"share":"https://www.laohu8.com/m/news/2175112192?lang=&edition=full","pubTime":"2021-10-15 23:33","market":"us","language":"en","title":"5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2175112192","media":"Motley Fool","summary":"These well-known and widely held companies should deliver jaw-dropping revenue growth over the next five years.","content":"<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.</p>\n<p>Yet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ffinancial-newspaper-graph-showing-gains-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Shopify: 464% implied sales growth by 2025</h2>\n<p>The first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform <b>Shopify</b> (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.</p>\n<p>The beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.</p>\n<p>What's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ftelemedicine-patient-doctor-physician-virtual-conference-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: 356% implied sales growth by 2025</h2>\n<p>Another big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.</p>\n<p>There's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.</p>\n<p>But this isn't a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.</p>\n<p>Teladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fretail-shopping-store-online-sale-smartphone-website-ecommerce-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: 430% implied sales growth by 2024</h2>\n<p>Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.</p>\n<p>Sea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.&nbsp; For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.</p>\n<p>Second, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.</p>\n<p>Third, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fsiblings-watch-tv-family-entertainment-show-network-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Roku: 408% implied sales growth by 2025</h2>\n<p>Television streaming platform <b>Roku</b> (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.</p>\n<p>Roku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).</p>\n<p>But the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fcoronavirus-vaccine-doctor-patient-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: 1,605% implied sales growth by 2025</h2>\n<p>However, the king of the mountain, at least on this list, is biotech stock <b>Moderna</b> (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!</p>\n<p>While it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.</p>\n<p>From a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.</p>\n<p>On the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175112192","content_text":"Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.\nYet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.\nImage source: Getty Images.\nShopify: 464% implied sales growth by 2025\nThe first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform Shopify (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.\nThe beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.\nWhat's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.\nImage source: Getty Images.\nTeladoc Health: 356% implied sales growth by 2025\nAnother big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin Teladoc Health (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.\nThere's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.\nBut this isn't a one-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.\nTeladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.\nImage source: Getty Images.\nSea Limited: 430% implied sales growth by 2024\nSingapore-based Sea Limited (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.\nSea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.  For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.\nSecond, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.\nThird, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.\nImage source: Getty Images.\nRoku: 408% implied sales growth by 2025\nTelevision streaming platform Roku (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.\nRoku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).\nBut the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.\nImage source: Getty Images.\nModerna: 1,605% implied sales growth by 2025\nHowever, the king of the mountain, at least on this list, is biotech stock Moderna (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!\nWhile it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.\nFrom a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.\nOn the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822372590,"gmtCreate":1634096770755,"gmtModify":1634096771021,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822372590","repostId":"1167212018","repostType":4,"repost":{"id":"1167212018","pubTimestamp":1634092916,"share":"https://www.laohu8.com/m/news/1167212018?lang=&edition=full","pubTime":"2021-10-13 10:41","market":"us","language":"en","title":"BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1167212018","media":"InvestorPlace","summary":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventu","content":"<p>One of the red-hot stocks that’s generating a lot of retail investor interest of late is&nbsp;<b>Vinco Ventures</b>(NASDAQ:<b><u>BBIG</u></b>). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past five trading days. Over this timeframe, BBIG stock has provided investors with gains of more than 20%. That is, for those with the guts to invest in this high-volatility name.</p>\n<p>Putting BBIG stock in perspective, this is a company that started the year around $1.35 per share. Since then, shares soared to nearly $12.50 per share last month before settling down to below $5 per share last week. What was a near 10-bagger has turned into a five-bagger. For those holding onto this stock long term, perhaps this volatility is nothing to be concerned with.</p>\n<p>One of the reasons behind the rapid ebb and flow of BBIG stock has been this company’s&nbsp;relatively high short interest. Indeed, any highly shorted stock is one that’s likely to give retail investors goosebumps. We’ve all seen the rallies in other short squeeze stocks this year.</p>\n<p>However, there’s another catalyst investors appear to be jumping on today. Let’s dive into what’s propelling Vinco Ventures higher right now.</p>\n<p>BBIG Stock Surges Ahead of Key Crypto Catalyst</p>\n<p>Today, investors appear to be pricing in enthusiasm around a key crypto update set to be unveiled this Friday. Vinco Ventures recently provided investors with a&nbsp;proxy statement&nbsp;for a spinoff. Titled&nbsp;<b>Cryptyde</b>, this spinoff will aim to allow the company to&nbsp;leverage its blockchain technologies&nbsp;further. By doing so, the company will “disrupt consumer facing industries.”</p>\n<p>Sounds good to me.</p>\n<p>Investors appear to be growing increasingly bullish on crypto-related stocks. Crypto prices have continued to surge in recent weeks. Accordingly, companies such as Vinco Ventures that are not only short-squeeze plays but also ones with crypto exposure, represent perhaps the holy grail for speculators right now.</p>\n<p>How this spinoff ultimately pans out remains to be seen. However, expectations are that BBIG stock could remain a highly volatile one for some time. Accordingly, this is a stock on my watchlist right now.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 10:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past ...</p>\n\n<a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167212018","content_text":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past five trading days. Over this timeframe, BBIG stock has provided investors with gains of more than 20%. That is, for those with the guts to invest in this high-volatility name.\nPutting BBIG stock in perspective, this is a company that started the year around $1.35 per share. Since then, shares soared to nearly $12.50 per share last month before settling down to below $5 per share last week. What was a near 10-bagger has turned into a five-bagger. For those holding onto this stock long term, perhaps this volatility is nothing to be concerned with.\nOne of the reasons behind the rapid ebb and flow of BBIG stock has been this company’s relatively high short interest. Indeed, any highly shorted stock is one that’s likely to give retail investors goosebumps. We’ve all seen the rallies in other short squeeze stocks this year.\nHowever, there’s another catalyst investors appear to be jumping on today. Let’s dive into what’s propelling Vinco Ventures higher right now.\nBBIG Stock Surges Ahead of Key Crypto Catalyst\nToday, investors appear to be pricing in enthusiasm around a key crypto update set to be unveiled this Friday. Vinco Ventures recently provided investors with a proxy statement for a spinoff. Titled Cryptyde, this spinoff will aim to allow the company to leverage its blockchain technologies further. By doing so, the company will “disrupt consumer facing industries.”\nSounds good to me.\nInvestors appear to be growing increasingly bullish on crypto-related stocks. Crypto prices have continued to surge in recent weeks. Accordingly, companies such as Vinco Ventures that are not only short-squeeze plays but also ones with crypto exposure, represent perhaps the holy grail for speculators right now.\nHow this spinoff ultimately pans out remains to be seen. However, expectations are that BBIG stock could remain a highly volatile one for some time. Accordingly, this is a stock on my watchlist right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":531,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829159740,"gmtCreate":1633482174945,"gmtModify":1633482175191,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still a falling knife&nbsp;","listText":"Still a falling knife&nbsp;","text":"Still a falling knife","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829159740","repostId":"2173911317","repostType":4,"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829164011,"gmtCreate":1633481487949,"gmtModify":1633481488214,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Dead cat rebound&nbsp;","listText":"Dead cat rebound&nbsp;","text":"Dead cat rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829164011","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=&edition=full","pubTime":"2021-10-02 13:35","market":"sh","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p>\n<ul>\n <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>\n <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>\n <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li>\n</ul>\n<p></p>\n<p>It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p>\n<p><b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p>\n<p>1. Crocs</p>\n<p>Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p>\n<p>The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p>\n<p>The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p>\n<p>Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p>\n<p>2. AMC Entertainment</p>\n<p>You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p>\n<p>However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p>\n<p>Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p>\n<p>3. Upstart</p>\n<p>I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p>\n<p>Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p>\n<p>With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864460267,"gmtCreate":1633139179949,"gmtModify":1633139635194,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","listText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","text":"Will report at the hell. Not worth trading [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864460267","repostId":"2172968387","repostType":4,"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889432961,"gmtCreate":1631167227953,"gmtModify":1631884166336,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","text":"$GameStop(GME)$Aviod, more downside to come.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889432961","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889183816,"gmtCreate":1631114512235,"gmtModify":1631889326757,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","listText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","text":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889183816","repostId":"1180788041","repostType":4,"repost":{"id":"1180788041","pubTimestamp":1631062558,"share":"https://www.laohu8.com/m/news/1180788041?lang=&edition=full","pubTime":"2021-09-08 08:55","market":"us","language":"en","title":"Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire","url":"https://stock-news.laohu8.com/highlight/detail?id=1180788041","media":"CNN Business","summary":"New York  - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.Last year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation exchange-traded fund. It surged nearly 150% in 2020","content":"<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.</p>\n<p>It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.</p>\n<p>Last year, Wood's strategy paid huge dividends for investors in her flagship&nbsp;Ark Innovation(ARKK)&nbsp;exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/120f0d157792edd784c8787a1c05e955\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Cathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.</span></p>\n<p>But this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.</p>\n<p>Wood wasn't available to comment for this story, but she doubled down in&nbsp;an interview with CNBC&nbsp;in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.</p>\n<p>\"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"</p>\n<p><b>How Wood developed her strategy</b></p>\n<p>Wood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.</p>\n<p>She worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.</p>\n<p>But then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.</p>\n<p>\"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she&nbsp;told Forbes&nbsp;in a 2014 interview.</p>\n<p>That focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.</p>\n<p>In the most prominent example, Wood remains an unabashed fan of&nbsp;Tesla(TSLA)&nbsp;and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's&nbsp;Autonomous Technology &amp; Robotics(ARKQ)&nbsp;and&nbsp;Next Generation Internet(ARKW)&nbsp;ETFs.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/425dc1ea59eb1c068eaba7a392e6c04d\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Wood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.</span></p>\n<p>Wood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.</p>\n<p>\"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"</p>\n<p>Ark's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an&nbsp;interview with Bloomberg Radio&nbsp;in August. She raved about Tesla's plans to&nbsp;build a humanoid robot, for example.</p>\n<p>\"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.</p>\n<p><b>Growth at all costs</b></p>\n<p>Wood recognizes her growth-at-all-costs way of investing is not for everyone.</p>\n<p>Tesla has lagged the broader market this year. Shares of&nbsp;Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.</p>\n<p>\"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said&nbsp;during a webcast&nbsp;hosted by Cboe Global Markets in March.</p>\n<p>Wood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.</p>\n<p>\"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"</p>\n<p>A colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.</p>\n<p>\"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\"&nbsp;Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told&nbsp;CNN Business in March.</p>\n<p><b>Wood's critics</b></p>\n<p>But a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.</p>\n<p>Some tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.</p>\n<p>Many of those tech funds imploded following the 2000 bubble. The<i>Wall Street Journal</i>wrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010&nbsp;with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"</p>\n<p>Is Wood destined for similar ignominy?</p>\n<p>Rivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in&nbsp;Roku(ROKU),Coinbase,Zoom(ZM)&nbsp;and&nbsp;Square(SQ).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02cbbe0138a0aaa5b930521275ad26e\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Roku is another example of a high-risk/high-reward stock that Wood loves.</span></p>\n<p>\"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.</p>\n<p>The top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF&nbsp;account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.</p>\n<p>For the time being, Wood is having the last laugh.</p>\n<p>Yes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&amp;P 500.</p>\n<p>As long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy ...</p>\n\n<a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180788041","content_text":"New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.\nIt's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.\nLast year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation(ARKK) exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.\nCathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.\nBut this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.\nWood wasn't available to comment for this story, but she doubled down in an interview with CNBC in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.\n\"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"\nHow Wood developed her strategy\nWood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.\nShe worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.\nBut then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.\n\"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she told Forbes in a 2014 interview.\nThat focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.\nIn the most prominent example, Wood remains an unabashed fan of Tesla(TSLA) and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's Autonomous Technology & Robotics(ARKQ) and Next Generation Internet(ARKW) ETFs.\nWood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.\nWood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.\n\"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"\nArk's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an interview with Bloomberg Radio in August. She raved about Tesla's plans to build a humanoid robot, for example.\n\"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.\nGrowth at all costs\nWood recognizes her growth-at-all-costs way of investing is not for everyone.\nTesla has lagged the broader market this year. Shares of Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.\n\"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by Cboe Global Markets in March.\nWood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.\n\"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"\nA colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.\n\"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\" Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told CNN Business in March.\nWood's critics\nBut a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.\nSome tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.\nMany of those tech funds imploded following the 2000 bubble. TheWall Street Journalwrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010 with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"\nIs Wood destined for similar ignominy?\nRivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in Roku(ROKU),Coinbase,Zoom(ZM) and Square(SQ).\nRoku is another example of a high-risk/high-reward stock that Wood loves.\n\"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.\nThe top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.\nFor the time being, Wood is having the last laugh.\nYes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&P 500.\nAs long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.","news_type":1},"isVote":1,"tweetType":1,"viewCount":36,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"repost":{"id":"1117851011","pubTimestamp":1631237804,"share":"https://www.laohu8.com/m/news/1117851011?lang=&edition=full","pubTime":"2021-09-10 09:36","market":"us","language":"en","title":"Cathie Wood’s Ark Invest Sells $110 Million In Tesla Stock As Insiders Also Dump Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1117851011","media":"Forbes","summary":"TOPLINE\nArk Invest, the New York City investment firm founded by famed Wall Street stock-picker Cath","content":"<p><b>TOPLINE</b></p>\n<p>Ark Invest, the New York City investment firm founded by famed Wall Street stock-picker Cathie Wood, sold off a massive stake in Tesla on Wednesday, joining a crop of insiders in cashing out of shares this week as the stock recovers from its lackluster performance this year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fc103935157e669bd98f2c9995a47698\" tg-width=\"960\" tg-height=\"540\" width=\"100%\" height=\"auto\"><span>Famed Wall Street money manager Cathie Wood has previously said the electric-vehicle company could ... [+] ELI WARREN FOR FORBES</span></p>\n<p><b>KEY FACTS</b></p>\n<p>According to Ark's daily transaction reports, three of the firm's funds, includings its flagship Ark Innovation ETF, sold a combined 142,708 shares of Tesla on Wednesday, representing a stake worth about $108 million and adding to separate sales of about $166 million since late July.</p>\n<p>The newest transactions come just days after Wood touted Tesla's success and gave shares a price target of $3,000 (nearly 300% more than current levels) in aninterviewwith Yahoo! Finance, saying the company's growing market share makes it poised to benefit from a nearly 18-fold increase in electric-vehicle sales by 2025.</p>\n<p>Though they've climbed about 6% over the last month, shares of Tesla, priced at about $757.50, are down nearly 15% from an all-time high in January.</p>\n<p>Meanwhile, Wood isn't alone among noteworthy Tesla investors selling off shares after the recent runup in prices: Three company officers, including two c-suite executives, sold about $4 million worth of stock in a series of transactions this week, according toregulatory filings.</p>\n<p>Ark and Tesla did not immediately respond to Forbes' requests for comment.</p>\n<p><b>SURPRISING FACT</b></p>\n<p>Though Wood is notably bullish on Tesla, the consensus on Wall Street doesn't reflect the same lofty expectations. According to Bloomberg data, the average analyst price target for Tesla shares is $701, suggesting shares could fall 8% over the next year.</p>\n<p><b>KEY BACKGROUND</b></p>\n<p>In the past, Wood has said Ark likes to trade around Tesla's outsized volatility, taking advantage of low prices to buy, and selling when she feels prices could take a hit. \"When we feel like analysts are hyperventilating about a stock—including Tesla—we naturally just take profits because we know we’re going to get another opportunity associated with controversy to buy the stock lower,” Woodsaidlast year after a wave of selling. Despite the recent sales, Tesla still makes up nearly 11% of Ark's flagship fund, which holds about 3.1 million shares worth a staggering $2.3 billion and alsoownsoutsized stakes in Coinbase, Zoom Video Communications and Spotify. On Wednesday, Ark also sold shares of chipmakers Nvidia and NXP Semiconductors, while picking up stock in software firm UiPath, real estate website Zillow and ecommerce companies Etsy and JD.com.</p>\n<p><b>TANGENT</b></p>\n<p>Technology stocks led the market's rally last year, generatingmassivereturns for tech-heavy investors like Ark. Starting this spring, however, accelerating economic growth and the threat ofrising interest ratesspurred a stock-market rotation away from growth stocks, like those in tech, to cyclical and value-leaning slices of the market that struggled during the pandemic (like energy and financials). Despite skyrocketing nearly 90% over the past year, the ARK Innovation ETF is up only 5% this year.</p>","source":"fors","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s Ark Invest Sells $110 Million In Tesla Stock As Insiders Also Dump Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s Ark Invest Sells $110 Million In Tesla Stock As Insiders Also Dump Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.forbes.com/sites/jonathanponciano/2021/09/09/cathie-woods-ark-invest-sells-110-million-in-tesla-stock-as-insiders-also-dump-shares/?sh=64a3239aed57><strong>Forbes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TOPLINE\nArk Invest, the New York City investment firm founded by famed Wall Street stock-picker Cathie Wood, sold off a massive stake in Tesla on Wednesday, joining a crop of insiders in cashing out ...</p>\n\n<a href=\"https://www.forbes.com/sites/jonathanponciano/2021/09/09/cathie-woods-ark-invest-sells-110-million-in-tesla-stock-as-insiders-also-dump-shares/?sh=64a3239aed57\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.forbes.com/sites/jonathanponciano/2021/09/09/cathie-woods-ark-invest-sells-110-million-in-tesla-stock-as-insiders-also-dump-shares/?sh=64a3239aed57","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117851011","content_text":"TOPLINE\nArk Invest, the New York City investment firm founded by famed Wall Street stock-picker Cathie Wood, sold off a massive stake in Tesla on Wednesday, joining a crop of insiders in cashing out of shares this week as the stock recovers from its lackluster performance this year.\nFamed Wall Street money manager Cathie Wood has previously said the electric-vehicle company could ... [+] ELI WARREN FOR FORBES\nKEY FACTS\nAccording to Ark's daily transaction reports, three of the firm's funds, includings its flagship Ark Innovation ETF, sold a combined 142,708 shares of Tesla on Wednesday, representing a stake worth about $108 million and adding to separate sales of about $166 million since late July.\nThe newest transactions come just days after Wood touted Tesla's success and gave shares a price target of $3,000 (nearly 300% more than current levels) in aninterviewwith Yahoo! Finance, saying the company's growing market share makes it poised to benefit from a nearly 18-fold increase in electric-vehicle sales by 2025.\nThough they've climbed about 6% over the last month, shares of Tesla, priced at about $757.50, are down nearly 15% from an all-time high in January.\nMeanwhile, Wood isn't alone among noteworthy Tesla investors selling off shares after the recent runup in prices: Three company officers, including two c-suite executives, sold about $4 million worth of stock in a series of transactions this week, according toregulatory filings.\nArk and Tesla did not immediately respond to Forbes' requests for comment.\nSURPRISING FACT\nThough Wood is notably bullish on Tesla, the consensus on Wall Street doesn't reflect the same lofty expectations. According to Bloomberg data, the average analyst price target for Tesla shares is $701, suggesting shares could fall 8% over the next year.\nKEY BACKGROUND\nIn the past, Wood has said Ark likes to trade around Tesla's outsized volatility, taking advantage of low prices to buy, and selling when she feels prices could take a hit. \"When we feel like analysts are hyperventilating about a stock—including Tesla—we naturally just take profits because we know we’re going to get another opportunity associated with controversy to buy the stock lower,” Woodsaidlast year after a wave of selling. Despite the recent sales, Tesla still makes up nearly 11% of Ark's flagship fund, which holds about 3.1 million shares worth a staggering $2.3 billion and alsoownsoutsized stakes in Coinbase, Zoom Video Communications and Spotify. On Wednesday, Ark also sold shares of chipmakers Nvidia and NXP Semiconductors, while picking up stock in software firm UiPath, real estate website Zillow and ecommerce companies Etsy and JD.com.\nTANGENT\nTechnology stocks led the market's rally last year, generatingmassivereturns for tech-heavy investors like Ark. Starting this spring, however, accelerating economic growth and the threat ofrising interest ratesspurred a stock-market rotation away from growth stocks, like those in tech, to cyclical and value-leaning slices of the market that struggled during the pandemic (like energy and financials). Despite skyrocketing nearly 90% over the past year, the ARK Innovation ETF is up only 5% this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"repost":{"id":"2175197255","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1634269620,"share":"https://www.laohu8.com/m/news/2175197255?lang=&edition=full","pubTime":"2021-10-15 11:47","market":"us","language":"en","title":"Avis stock falls after Morgan Stanley recommends selling, saying it's too early for the 'mega-fleet bull case'","url":"https://stock-news.laohu8.com/highlight/detail?id=2175197255","media":"Dow Jones","summary":"Avis stock falls after Morgan Stanley recommends selling, saying it's too early for the 'mega-fleet ","content":"<p>Avis stock falls after <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> recommends selling, saying it's too early for the 'mega-fleet bull case'</p>\n<p>Shares of Avis Budget Group Inc. <a href=\"https://laohu8.com/S/CAR\">$(CAR)$</a> dropped 2.5% in afternoon trading Thursday, after Morgan Stanley analyst Billy Kovanis recommended investors sell, saying it's too early for investors to be betting on the \"mega-fleet bull case.\" The stock has now lost 4.8% since it closed at a record $153.39 on Tuesday, but has still more than doubled (up 103.6%) over the past three months and rocketed 291.6% year to date, while the S&amp;P 500 has advanced just 18.1% this year. Kovanis downgraded Avis to underweight, after cutting the rating to equal weight in March 2021. Although he raised his tock price target to $110 from $85, the new target still implied about 25% downside from current levels. He said he just doesn't buy that investor suddenly view car rental as a high return-on-invested-capital <a href=\"https://laohu8.com/S/ROIC\">$(ROIC)$</a> business in the long run, and that pricing, which has been boosted recently by increased travel and lack of supply, will be permanently higher. \"Pricing may very well be higher for a year or two, but we don't see this as a 3-to-5 year phenomenon,\" Kovanis wrote in a note to clients. He added that rental car stocks are \"notably cyclical,\" so that means, \"what goes up, must come down.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avis stock falls after Morgan Stanley recommends selling, saying it's too early for the 'mega-fleet bull case'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvis stock falls after Morgan Stanley recommends selling, saying it's too early for the 'mega-fleet bull case'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-10-15 11:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Avis stock falls after <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> recommends selling, saying it's too early for the 'mega-fleet bull case'</p>\n<p>Shares of Avis Budget Group Inc. <a href=\"https://laohu8.com/S/CAR\">$(CAR)$</a> dropped 2.5% in afternoon trading Thursday, after Morgan Stanley analyst Billy Kovanis recommended investors sell, saying it's too early for investors to be betting on the \"mega-fleet bull case.\" The stock has now lost 4.8% since it closed at a record $153.39 on Tuesday, but has still more than doubled (up 103.6%) over the past three months and rocketed 291.6% year to date, while the S&amp;P 500 has advanced just 18.1% this year. Kovanis downgraded Avis to underweight, after cutting the rating to equal weight in March 2021. Although he raised his tock price target to $110 from $85, the new target still implied about 25% downside from current levels. He said he just doesn't buy that investor suddenly view car rental as a high return-on-invested-capital <a href=\"https://laohu8.com/S/ROIC\">$(ROIC)$</a> business in the long run, and that pricing, which has been boosted recently by increased travel and lack of supply, will be permanently higher. \"Pricing may very well be higher for a year or two, but we don't see this as a 3-to-5 year phenomenon,\" Kovanis wrote in a note to clients. He added that rental car stocks are \"notably cyclical,\" so that means, \"what goes up, must come down.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAR":"安飞士"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175197255","content_text":"Avis stock falls after Morgan Stanley recommends selling, saying it's too early for the 'mega-fleet bull case'\nShares of Avis Budget Group Inc. $(CAR)$ dropped 2.5% in afternoon trading Thursday, after Morgan Stanley analyst Billy Kovanis recommended investors sell, saying it's too early for investors to be betting on the \"mega-fleet bull case.\" The stock has now lost 4.8% since it closed at a record $153.39 on Tuesday, but has still more than doubled (up 103.6%) over the past three months and rocketed 291.6% year to date, while the S&P 500 has advanced just 18.1% this year. Kovanis downgraded Avis to underweight, after cutting the rating to equal weight in March 2021. Although he raised his tock price target to $110 from $85, the new target still implied about 25% downside from current levels. He said he just doesn't buy that investor suddenly view car rental as a high return-on-invested-capital $(ROIC)$ business in the long run, and that pricing, which has been boosted recently by increased travel and lack of supply, will be permanently higher. \"Pricing may very well be higher for a year or two, but we don't see this as a 3-to-5 year phenomenon,\" Kovanis wrote in a note to clients. He added that rental car stocks are \"notably cyclical,\" so that means, \"what goes up, must come down.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":798,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=&edition=full","pubTime":"2021-10-02 13:35","market":"sh","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p>\n<ul>\n <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>\n <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>\n <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li>\n</ul>\n<p></p>\n<p>It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p>\n<p><b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p>\n<p>1. Crocs</p>\n<p>Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p>\n<p>The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p>\n<p>The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p>\n<p>Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p>\n<p>2. AMC Entertainment</p>\n<p>You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p>\n<p>However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p>\n<p>Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p>\n<p>3. Upstart</p>\n<p>I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p>\n<p>Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p>\n<p>With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"repost":{"id":"2172614079","pubTimestamp":1633236989,"share":"https://www.laohu8.com/m/news/2172614079?lang=&edition=full","pubTime":"2021-10-03 12:56","market":"us","language":"en","title":"3 Unstoppable Stocks to Buy if There's a Stock Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2172614079","media":"Motley Fool","summary":"Short-term pain can lead to long-term gain for opportunistic investors.","content":"<p>For 18 months, Wall Street and investors have enjoyed a historic bounce-back rally in the <b>S&amp;P 500</b> (SNPINDEX:^GSPC). After shedding a third of its value in under five weeks, the widely followed index doubled from its bear-market bottom in less than 17 months.</p>\n<p>Unfortunately, all rallies eventually come to an end on Wall Street.</p>\n<p>Even though we can't precisely predict when a stock market crash will happen, how long it'll last, how steep the decline will be, or even what'll trigger it ahead of time, we do know that crashes and corrections are normal occurrences -- and <a href=\"https://laohu8.com/S/AONE.U\">one</a> could be brewing.</p>\n<h2>A stock market crash could be coming</h2>\n<p>History offers one clue as to why the current record-breaking rally could end. Following each of the previous eight bear-market bottoms, dating back to 1960, the benchmark S&amp;P 500 has had either one or two double-digit percentage declines within three years. We're halfway to that point and haven't yet seen a notable correction.</p>\n<p>Another chief concern is valuation. The S&amp;P 500 ended Sept. 27 with a Shiller price-to-earnings (P/E) ratio of 38.4. The Shiller P/E examines inflation-adjusted earnings over the past 10 years. A reading of 38.4 for the S&amp;P 500 is nearly a two-decade high and well more than double the 151-year average reading for the index. More importantly, the previous four times the Shiller P/E ratio surpassed 30, the index subsequently lost at least 20%.</p>\n<p>Rising margin debt is also worrisome. Margin debt describes the amount of money being borrowed with interest to buy or short-sell securities. While it's not uncommon to see margin debt increase over time, it is uncharacteristic to see margin debt rise rapidly over a short time frame.</p>\n<p>There have been three instances over the past quarter of a century where margin debt rose by 60% or more in a single year. One of those instances occurred this year. The previous two directly preceded the popping of the dot-com bubble and the Great Recession.</p>\n<p>And, as noted, crashes and corrections are par for the course when investing in the greatest long-term wealth creator on the planet. There have been 38 double-digit percentage crashes or corrections in the S&amp;P 500 since the beginning of 1950. This works out to a correction every 1.87 years. Although Wall Street doesn't strictly adhere to averages, it does put into perspective how common it is for equities to swoon from time to time.</p>\n<h2>A crash would be the perfect time to buy these unstoppable stocks</h2>\n<p>While stock market crashes and steep corrections have a tendency to put investors on edge, they're actually the perfect opportunity to go shopping. All notable moves lower in the stock market have eventually been erased by a bull market rally. Buying great companies and being patient is usually a wealth-building recipe.</p>\n<p>If the market were to crash or undergo a steep correction, buying this trio of unstoppable stocks would be a wise move.</p>\n<h2>Mastercard</h2>\n<p>Although financial stocks are highly cyclical, payment-processing behemoth <b>Mastercard</b> (NYSE:MA) could certainly be described as unstoppable, and would be perfect to scoop up at a discount were a crash or correction to arise.</p>\n<p>Believe it or not, the cyclical nature of Mastercard's operations is arguably its greatest strength. Yes, periods of economic contraction and recessions are inevitable. When domestic and global economies struggle, businesses and people spend less, which means less in the way of merchant revenue for Mastercard. However, periods of contraction usually last for a few months or a couple of quarters, at most. By comparison, the last economic expansion in the U.S. lasted 11 years. Mastercard benefits immensely from these disproportionately long periods of expansion domestically and abroad.</p>\n<p>Mastercard's success is also a function of its focus. This is a company that strictly deals with the processing side of the equation and has resisted the urge to become a lender. While not lending is, in theory, costing the company the opportunity to generate interest and fee income, it also means Mastercard has no liability when credit delinquencies rise during recessions. Not having to set aside capital to cover credit losses is a big reason the company's profit margin has stayed above 40%.</p>\n<p>Additionally, a majority of the world's transactions are still being conducted in cash. Mastercard has a long runway with which to push its payments infrastructure into emerging and underbanked regions of the world.</p>\n<h2>NextEra Energy</h2>\n<p>For conservative investors who favor minimal volatility and steady income, electric utility stock <b>NextEra Energy</b> (NYSE:NEE) would be a really smart place to put your money to work if a stock market crash occurs.</p>\n<p>The first thing working in NextEra's favor is that it supplies a basic need service: Electricity. No matter how well or poorly the stock market or U.S. economy are performing, demand for electricity among homeowners and renters doesn't fluctuate much from year to year. Being a supplier of electricity means NextEra can count on highly predictable cash flow, which helps its management team outlay capital for projects without compromising the company's profitability or its payout.</p>\n<p>What really sets NextEra Energy apart is its renewable energy focus. No utility in the U.S. is currently generating more capacity from solar or wind power than NextEra. And with the company plowing $50 billion to $55 billion (in aggregate) into new infrastructure projects between 2020 and 2022, no company is going to be anywhere close to NextEra in terms of renewable power generation for a long time to come.</p>\n<p>Although these projects aren't cheap, they're substantially lowering electricity generation costs and have lifted the company's compound annual growth rate to the high single digits for more than a decade. In comparison, most electric utilities have a low single-digit growth rate.</p>\n<p>A final layer of safety can be found with the company's regulated utility operations (i.e., those not powered by renewable sources). Though regulated utilities can't hike their prices at will, they also aren't exposed to potentially volatile wholesale electricity pricing. Thus, NextEra's regulated operations add to the predictability of its cash flow.</p>\n<h2>Amazon</h2>\n<p>The third unstoppable stock to buy if a market crash occurs is dominant e-commerce player <b>Amazon</b> (NASDAQ:AMZN).</p>\n<p>When I say Amazon is a dominant online retailer, I mean it in every sense of the word. When eMarketer released a report in late April examining U.S. online sales market share in 2021, it estimated Amazon would control roughly $0.40 of every $1 spent domestically. <b>Walmart</b>&nbsp;is the second-largest online retailer by market share, and Amazon has more than five times its share.</p>\n<p>But Amazon is keenly aware that retail margins aren't the best. That's why it's actively promoted its subscription Prime service. Amazon is collecting tens of billions in revenue each year from its subscriptions, which plays a key role in buoying thin retail margins and ensures the company can undercut brick-and-mortar retailers on price. Prime members are also given incentive to stay within the Amazon ecosystem of products and services.</p>\n<p>What's too often overlooked with Amazon is that it's also the most dominant company in cloud infrastructure services. Amazon Web Services (AWS) is currently pacing more than $59 billion in annual run-rate sales, and AWS brought in close to a third of global cloud infrastructure spend in the first quarter, according to Canalys.</p>\n<p>This is important, because cloud and subscription services offer considerably juicier margins than online retail sales. As a result, these segments should play a key role in more than doubling Amazon's operating cash flow by mid-decade.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks to Buy if There's a Stock Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks to Buy if There's a Stock Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 12:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/02/3-unstoppable-stocks-to-buy-if-stock-market-crash/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For 18 months, Wall Street and investors have enjoyed a historic bounce-back rally in the S&P 500 (SNPINDEX:^GSPC). After shedding a third of its value in under five weeks, the widely followed index ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/3-unstoppable-stocks-to-buy-if-stock-market-crash/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SH":"标普500反向ETF","OEF":"标普100指数ETF-iShares","SSO":"两倍做多标普500ETF","UPRO":"三倍做多标普500ETF","SDS":"两倍做空标普500ETF","IVV":"标普500指数ETF","AMZN":"亚马逊","OEX":"标普100","SPXU":"三倍做空标普500ETF",".SPX":"S&P 500 Index","MA":"万事达"},"source_url":"https://www.fool.com/investing/2021/10/02/3-unstoppable-stocks-to-buy-if-stock-market-crash/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172614079","content_text":"For 18 months, Wall Street and investors have enjoyed a historic bounce-back rally in the S&P 500 (SNPINDEX:^GSPC). After shedding a third of its value in under five weeks, the widely followed index doubled from its bear-market bottom in less than 17 months.\nUnfortunately, all rallies eventually come to an end on Wall Street.\nEven though we can't precisely predict when a stock market crash will happen, how long it'll last, how steep the decline will be, or even what'll trigger it ahead of time, we do know that crashes and corrections are normal occurrences -- and one could be brewing.\nA stock market crash could be coming\nHistory offers one clue as to why the current record-breaking rally could end. Following each of the previous eight bear-market bottoms, dating back to 1960, the benchmark S&P 500 has had either one or two double-digit percentage declines within three years. We're halfway to that point and haven't yet seen a notable correction.\nAnother chief concern is valuation. The S&P 500 ended Sept. 27 with a Shiller price-to-earnings (P/E) ratio of 38.4. The Shiller P/E examines inflation-adjusted earnings over the past 10 years. A reading of 38.4 for the S&P 500 is nearly a two-decade high and well more than double the 151-year average reading for the index. More importantly, the previous four times the Shiller P/E ratio surpassed 30, the index subsequently lost at least 20%.\nRising margin debt is also worrisome. Margin debt describes the amount of money being borrowed with interest to buy or short-sell securities. While it's not uncommon to see margin debt increase over time, it is uncharacteristic to see margin debt rise rapidly over a short time frame.\nThere have been three instances over the past quarter of a century where margin debt rose by 60% or more in a single year. One of those instances occurred this year. The previous two directly preceded the popping of the dot-com bubble and the Great Recession.\nAnd, as noted, crashes and corrections are par for the course when investing in the greatest long-term wealth creator on the planet. There have been 38 double-digit percentage crashes or corrections in the S&P 500 since the beginning of 1950. This works out to a correction every 1.87 years. Although Wall Street doesn't strictly adhere to averages, it does put into perspective how common it is for equities to swoon from time to time.\nA crash would be the perfect time to buy these unstoppable stocks\nWhile stock market crashes and steep corrections have a tendency to put investors on edge, they're actually the perfect opportunity to go shopping. All notable moves lower in the stock market have eventually been erased by a bull market rally. Buying great companies and being patient is usually a wealth-building recipe.\nIf the market were to crash or undergo a steep correction, buying this trio of unstoppable stocks would be a wise move.\nMastercard\nAlthough financial stocks are highly cyclical, payment-processing behemoth Mastercard (NYSE:MA) could certainly be described as unstoppable, and would be perfect to scoop up at a discount were a crash or correction to arise.\nBelieve it or not, the cyclical nature of Mastercard's operations is arguably its greatest strength. Yes, periods of economic contraction and recessions are inevitable. When domestic and global economies struggle, businesses and people spend less, which means less in the way of merchant revenue for Mastercard. However, periods of contraction usually last for a few months or a couple of quarters, at most. By comparison, the last economic expansion in the U.S. lasted 11 years. Mastercard benefits immensely from these disproportionately long periods of expansion domestically and abroad.\nMastercard's success is also a function of its focus. This is a company that strictly deals with the processing side of the equation and has resisted the urge to become a lender. While not lending is, in theory, costing the company the opportunity to generate interest and fee income, it also means Mastercard has no liability when credit delinquencies rise during recessions. Not having to set aside capital to cover credit losses is a big reason the company's profit margin has stayed above 40%.\nAdditionally, a majority of the world's transactions are still being conducted in cash. Mastercard has a long runway with which to push its payments infrastructure into emerging and underbanked regions of the world.\nNextEra Energy\nFor conservative investors who favor minimal volatility and steady income, electric utility stock NextEra Energy (NYSE:NEE) would be a really smart place to put your money to work if a stock market crash occurs.\nThe first thing working in NextEra's favor is that it supplies a basic need service: Electricity. No matter how well or poorly the stock market or U.S. economy are performing, demand for electricity among homeowners and renters doesn't fluctuate much from year to year. Being a supplier of electricity means NextEra can count on highly predictable cash flow, which helps its management team outlay capital for projects without compromising the company's profitability or its payout.\nWhat really sets NextEra Energy apart is its renewable energy focus. No utility in the U.S. is currently generating more capacity from solar or wind power than NextEra. And with the company plowing $50 billion to $55 billion (in aggregate) into new infrastructure projects between 2020 and 2022, no company is going to be anywhere close to NextEra in terms of renewable power generation for a long time to come.\nAlthough these projects aren't cheap, they're substantially lowering electricity generation costs and have lifted the company's compound annual growth rate to the high single digits for more than a decade. In comparison, most electric utilities have a low single-digit growth rate.\nA final layer of safety can be found with the company's regulated utility operations (i.e., those not powered by renewable sources). Though regulated utilities can't hike their prices at will, they also aren't exposed to potentially volatile wholesale electricity pricing. Thus, NextEra's regulated operations add to the predictability of its cash flow.\nAmazon\nThe third unstoppable stock to buy if a market crash occurs is dominant e-commerce player Amazon (NASDAQ:AMZN).\nWhen I say Amazon is a dominant online retailer, I mean it in every sense of the word. When eMarketer released a report in late April examining U.S. online sales market share in 2021, it estimated Amazon would control roughly $0.40 of every $1 spent domestically. Walmart is the second-largest online retailer by market share, and Amazon has more than five times its share.\nBut Amazon is keenly aware that retail margins aren't the best. That's why it's actively promoted its subscription Prime service. Amazon is collecting tens of billions in revenue each year from its subscriptions, which plays a key role in buoying thin retail margins and ensures the company can undercut brick-and-mortar retailers on price. Prime members are also given incentive to stay within the Amazon ecosystem of products and services.\nWhat's too often overlooked with Amazon is that it's also the most dominant company in cloud infrastructure services. Amazon Web Services (AWS) is currently pacing more than $59 billion in annual run-rate sales, and AWS brought in close to a third of global cloud infrastructure spend in the first quarter, according to Canalys.\nThis is important, because cloud and subscription services offer considerably juicier margins than online retail sales. As a result, these segments should play a key role in more than doubling Amazon's operating cash flow by mid-decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","pubTimestamp":1639806035,"share":"https://www.laohu8.com/m/news/1161245886?lang=&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p>\n<p>\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p>\n<p>Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p>\n<p>\"This is an opportunity, not the start of a downtrend for tech,\" he said.</p>\n<p>Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p>\n<p>He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p>\n<p>That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p>\n<p>\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p>\n<p>Rather, Ives suggested investors \"double down on their winners.\"</p>\n<p>Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p>\n<p>The main laggard in the group is CYBR, which is basically flat on the year:</p>\n<p><img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 13:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"...</p>\n\n<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1},"isVote":1,"tweetType":1,"viewCount":1061,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895424082,"gmtCreate":1628767853846,"gmtModify":1631889326805,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Not worth buying. Follow her and die faster&nbsp;","listText":"Not worth buying. Follow her and die faster&nbsp;","text":"Not worth buying. Follow her and die faster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/895424082","repostId":"2158257251","repostType":4,"repost":{"id":"2158257251","pubTimestamp":1628767260,"share":"https://www.laohu8.com/m/news/2158257251?lang=&edition=full","pubTime":"2021-08-12 19:21","market":"us","language":"en","title":"Buy This Top Cathie Wood Stock Before It Breaks Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2158257251","media":"Motley Fool","summary":"This cloud stock is the ninth-largest holding in Wood's ARK Innovation ETF, and it recently became an attractive buy.","content":"<p>Cathie Wood, the founder and CEO of ARK Invest, has gained immense popularity among retail investors thanks to strong performance from many of the company's exchange-traded funds (ETFs). The stock price of the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b>, for instance, has soared close to 150% since the beginning of 2020 and crushed the broader stock market's gains handsomely.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/845dfc5a66c843b06f22e65938d896a0\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>ARKK data by YCharts</span></p>\n<p>The terrific gains are a result of Wood's strategy of investing in disruptive tech companies, such as cloud communications specialist <b>Twilio</b> (NYSE:TWLO). Twilio is among the top 10 holdings in the ARK Innovation ETF, accounting&nbsp;for 3.66% of the fund's value. The stock has more than tripled in value since January 2020, but investors who have missed this terrific rally now have a golden opportunity to go long Twilio. Let's see why.</p>\n<h2>Twilio's latest slip is an opportunity in disguise</h2>\n<p>Twilio stock price fell after the company released its Q2 earnings report, which seems surprising as it easily beat Wall Street's expectations. It reported a 67% year-over-year increase in revenue to $669 million, while non-GAAP loss per share increased from $0.09 in the prior-year period to $0.11 last quarter.</p>\n<p>Analysts expected Twilio to lose $0.13 per share on $598 million in revenue. However, it looks like Twilio's guidance for a bigger-than-expected loss this quarter may have triggered some panic among investors. Twilio expects&nbsp;to lose between $0.14 and $0.17 per share this quarter on revenue between $670 million and $680 million. Wall Street was expecting&nbsp;a smaller loss of $0.07 per share on $636.4 million in revenue.</p>\n<p>But investors shouldn't be focusing on Twilio's near-term bottom-line miss, as it is pulling the right strings to ensure growth in a lucrative market. Its revenue is on track to increase 50% to 52% year over year this quarter -- but don't be surprised to see Twilio do better than that, for a couple of reasons.</p>\n<p>First, the company's customer base is expanding at a quick pace. It finished Q2 with 240,000 customer accounts, compared to 200,000 in the year-ago period. The acquisitions&nbsp;of Segment and ValueFirst accounted for 7,500 of those customer additions.</p>\n<p>Second, Twilio is generating incremental business from existing customers. This is evident from the company's dollar-based net expansion rate of 135% in Q2, up from 132% in the prior-year period. The dollar-based net expansion rate increases when Twilio's active customers increase their usage of products they are already using or buy additional services from the company.</p>\n<p>It is worth noting that the metric wasn't impacted by the acquisitions of Segment and ValueFirst, as the dollar-based net expansion rate is calculated based on those active customer accounts that were present in the prior-year period. The new customers brought in by those acquisitions can boost spending if they decide to opt for Twilio's other products. Additionally, Twilio's existing customer base now has additional services to choose from, paving the way for further growth in the dollar-based net expansion rate in future quarters.</p>\n<p>Investors shouldn't forget that Twilio added another fast-growing company to its portfolio recently. The company recently spent $850 million&nbsp;to acquire toll-free messaging provider Zipwhip, bringing 30,000 new customers&nbsp;into its fold.</p>\n<p>Now, this acquisition-driven strategy is impacting the company's bottom-line performance because of acquisition-related expenses. For instance, it incurred $2.5 million in expenses to acquire Zipwhip. But investors shouldn't miss the forest for the trees, as Twilio's strategy of spending money to boost its top line will come in handy in the long run.</p>\n<h2>Focus on the bigger picture</h2>\n<p>Twilio is focused on grabbing as big a piece of the cloud communications market as possible. This is a smart thing to do, as the cloud communications market is expected to clock a compound annual growth rate of nearly 28% through 2026, and Twilio is currently growing at a faster pace than the space it operates in.</p>\n<p>The company's acquisitions indicate that it intends to keep outpacing the broader industry's growth, a strategy that could substantially boost revenue in the long run and eventually pave the way for bottom-line improvements. Twilio estimates that its addressable market could hit&nbsp;$87 billion by 2023, a number that rises to $104 billion&nbsp;after including the revenue opportunity added by Segment.</p>\n<p>So Twilio is just scratching the surface of a massive opportunity given that it has generated $2.25 billion in revenue in the past year. As such, it should be able to sustain its high levels of growth in the long run. That's why investors looking to add a growth stock to their portfolios can treat the recent slip in Twilio as a buying opportunity.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy This Top Cathie Wood Stock Before It Breaks Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy This Top Cathie Wood Stock Before It Breaks Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-12 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/12/buy-top-cathie-wood-stock-before-breaks-higher/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood, the founder and CEO of ARK Invest, has gained immense popularity among retail investors thanks to strong performance from many of the company's exchange-traded funds (ETFs). The stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/12/buy-top-cathie-wood-stock-before-breaks-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc"},"source_url":"https://www.fool.com/investing/2021/08/12/buy-top-cathie-wood-stock-before-breaks-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158257251","content_text":"Cathie Wood, the founder and CEO of ARK Invest, has gained immense popularity among retail investors thanks to strong performance from many of the company's exchange-traded funds (ETFs). The stock price of the ARK Innovation ETF, for instance, has soared close to 150% since the beginning of 2020 and crushed the broader stock market's gains handsomely.\nARKK data by YCharts\nThe terrific gains are a result of Wood's strategy of investing in disruptive tech companies, such as cloud communications specialist Twilio (NYSE:TWLO). Twilio is among the top 10 holdings in the ARK Innovation ETF, accounting for 3.66% of the fund's value. The stock has more than tripled in value since January 2020, but investors who have missed this terrific rally now have a golden opportunity to go long Twilio. Let's see why.\nTwilio's latest slip is an opportunity in disguise\nTwilio stock price fell after the company released its Q2 earnings report, which seems surprising as it easily beat Wall Street's expectations. It reported a 67% year-over-year increase in revenue to $669 million, while non-GAAP loss per share increased from $0.09 in the prior-year period to $0.11 last quarter.\nAnalysts expected Twilio to lose $0.13 per share on $598 million in revenue. However, it looks like Twilio's guidance for a bigger-than-expected loss this quarter may have triggered some panic among investors. Twilio expects to lose between $0.14 and $0.17 per share this quarter on revenue between $670 million and $680 million. Wall Street was expecting a smaller loss of $0.07 per share on $636.4 million in revenue.\nBut investors shouldn't be focusing on Twilio's near-term bottom-line miss, as it is pulling the right strings to ensure growth in a lucrative market. Its revenue is on track to increase 50% to 52% year over year this quarter -- but don't be surprised to see Twilio do better than that, for a couple of reasons.\nFirst, the company's customer base is expanding at a quick pace. It finished Q2 with 240,000 customer accounts, compared to 200,000 in the year-ago period. The acquisitions of Segment and ValueFirst accounted for 7,500 of those customer additions.\nSecond, Twilio is generating incremental business from existing customers. This is evident from the company's dollar-based net expansion rate of 135% in Q2, up from 132% in the prior-year period. The dollar-based net expansion rate increases when Twilio's active customers increase their usage of products they are already using or buy additional services from the company.\nIt is worth noting that the metric wasn't impacted by the acquisitions of Segment and ValueFirst, as the dollar-based net expansion rate is calculated based on those active customer accounts that were present in the prior-year period. The new customers brought in by those acquisitions can boost spending if they decide to opt for Twilio's other products. Additionally, Twilio's existing customer base now has additional services to choose from, paving the way for further growth in the dollar-based net expansion rate in future quarters.\nInvestors shouldn't forget that Twilio added another fast-growing company to its portfolio recently. The company recently spent $850 million to acquire toll-free messaging provider Zipwhip, bringing 30,000 new customers into its fold.\nNow, this acquisition-driven strategy is impacting the company's bottom-line performance because of acquisition-related expenses. For instance, it incurred $2.5 million in expenses to acquire Zipwhip. But investors shouldn't miss the forest for the trees, as Twilio's strategy of spending money to boost its top line will come in handy in the long run.\nFocus on the bigger picture\nTwilio is focused on grabbing as big a piece of the cloud communications market as possible. This is a smart thing to do, as the cloud communications market is expected to clock a compound annual growth rate of nearly 28% through 2026, and Twilio is currently growing at a faster pace than the space it operates in.\nThe company's acquisitions indicate that it intends to keep outpacing the broader industry's growth, a strategy that could substantially boost revenue in the long run and eventually pave the way for bottom-line improvements. Twilio estimates that its addressable market could hit $87 billion by 2023, a number that rises to $104 billion after including the revenue opportunity added by Segment.\nSo Twilio is just scratching the surface of a massive opportunity given that it has generated $2.25 billion in revenue in the past year. As such, it should be able to sustain its high levels of growth in the long run. That's why investors looking to add a growth stock to their portfolios can treat the recent slip in Twilio as a buying opportunity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"repost":{"id":"2175112192","pubTimestamp":1634312035,"share":"https://www.laohu8.com/m/news/2175112192?lang=&edition=full","pubTime":"2021-10-15 23:33","market":"us","language":"en","title":"5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2175112192","media":"Motley Fool","summary":"These well-known and widely held companies should deliver jaw-dropping revenue growth over the next five years.","content":"<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.</p>\n<p>Yet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ffinancial-newspaper-graph-showing-gains-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"535\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Shopify: 464% implied sales growth by 2025</h2>\n<p>The first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform <b>Shopify</b> (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.</p>\n<p>The beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.</p>\n<p>What's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Ftelemedicine-patient-doctor-physician-virtual-conference-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: 356% implied sales growth by 2025</h2>\n<p>Another big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.</p>\n<p>There's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.</p>\n<p>But this isn't a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.</p>\n<p>Teladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fretail-shopping-store-online-sale-smartphone-website-ecommerce-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Sea Limited: 430% implied sales growth by 2024</h2>\n<p>Singapore-based <b>Sea Limited</b> (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.</p>\n<p>Sea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.&nbsp; For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.</p>\n<p>Second, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.</p>\n<p>Third, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fsiblings-watch-tv-family-entertainment-show-network-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Roku: 408% implied sales growth by 2025</h2>\n<p>Television streaming platform <b>Roku</b> (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.</p>\n<p>Roku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).</p>\n<p>But the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646435%2Fcoronavirus-vaccine-doctor-patient-healthcare-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna: 1,605% implied sales growth by 2025</h2>\n<p>However, the king of the mountain, at least on this list, is biotech stock <b>Moderna</b> (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!</p>\n<p>While it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.</p>\n<p>From a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.</p>\n<p>On the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Big-Name Stocks Expected to Increase Sales 356% to 1,605% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/15/5-big-name-stocks-increase-sales-356-to-1605/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175112192","content_text":"Since the Great Recession ended more than 12 years ago, growth stocks have ruled the roost on Wall Street. A combination of historically low lending rates and ongoing quantitative easing measures from the Federal Reserve have rolled out the red carpet for fast-paced companies and given them access to abundant cheap capital.\nYet for some high-growth stocks, their parabolic sales increases are just beginning. Based on analysts' consensus sales estimates, the following five big-name stocks are expected to increase their sales by 356% to as much as 1,605% by 2025.\nImage source: Getty Images.\nShopify: 464% implied sales growth by 2025\nThe first well-known hypergrowth stock that could deliver a jaw-dropping sales increase over the next five years is cloud-based e-commerce platform Shopify (NYSE:SHOP). Following $2.93 billion in full-year sales in 2020, Wall Street is forecasting $16.54 billion in annual sales by mid-decade. That's a 464% increase, for those of you keeping score at home.\nThe beauty of the Shopify operating model is that it finds itself in the right place at the right time. Prior to 2020, businesses were shifting their presence online at a steady pace. But in the wake of the pandemic, businesses of all sizes have come to realize how important it is to have their products available for sale on e-commerce marketplaces. Known best for helping small merchants reach large audiences, Shopify estimates its total addressable market for small businesses is currently $153 billion. Thus, with $2.9 billion in sales last year and the company constantly innovating and introducing new tools, it's just scratching the tip of the iceberg in terms of its potential.\nWhat's more, Shopify is benefiting from its high-margin subscription-based services. Whereas entrepreneurs can take advantage of the company's basic services for $29 a month, it offers its core service to small businesses for $79/mo. to $299/mo., or its Shopify Plus service for $2,000/mo. to larger businesses. This is a company that shouldn't have any issue growing its operating margins over time.\nImage source: Getty Images.\nTeladoc Health: 356% implied sales growth by 2025\nAnother big-name stock on track to produce eye-popping sales growth over the next half-decade is telemedicine kingpin Teladoc Health (NYSE:TDOC). Last year, Teladoc generated $1.09 billion in sales. But by 2025, Wall Street's consensus has the company pegged for $4.98 billion in sales.\nThere's little question that Teladoc Health benefited immensely from the COVID-19 pandemic. With physicians wanting to keep potentially sick and high-risk people out of their offices, demand for virtual visits soared.\nBut this isn't a one-trick pony. What Teladoc is doing is fundamentally altering the personalized treatment landscape. While virtual services won't replace all in-person visits, it's far more convenient for patients, and it can help doctors keep better tabs on chronically ill patients. Ultimately, that's a recipe for improved patient outcomes and less money out of the pockets of health insurers.\nTeladoc also expects a serious long-term growth boost from the acquisition of leading applied health signals company Livongo Health. Livongo leans on artificial intelligence to send tips to its chronic care members to help them lead healthier lives. With a focus on diabetes, hypertension, and weight management, Livongo's services could cater to a large swath of the U.S. adult population.\nImage source: Getty Images.\nSea Limited: 430% implied sales growth by 2024\nSingapore-based Sea Limited (NYSE:SE) is expected to deliver such robust sales growth that it doesn't even need a full five years. With consensus estimates looking out to 2024, the company's sales are projected to more than quintuple to $23.2 billion from $4.38 billion in 2020.\nSea's success is the result of three very different but rapidly growing segments. The first, digital entertainment, is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea had approximately 725 million quarterly active mobile game users in the June-ended quarter, 12.7% of which were paying customers.  For some context, only about 2% of mobile gamers are being converted to paying customers industrywide.\nSecond, and arguably the more intriguing segment, is its e-commerce platform Shopee. Shopee has consistently been the most downloaded shopping app in Southeastern Asia, and it managed $15 billion in gross merchandise value (GMV) on its platform in the second quarter. This $60 billion annual run-rate is a 500% increase from what it did in all of 2018 ($10 billion in GMV). E-commerce sales in the emerging market countries Shopee serves are still in the early stages of ramping up.\nThird, Sea's digital financial services segment has almost 33 million paying digital wallet customers. Since many of the markets Sea serves are underbanked, mobile wallets could be a key growth driver for the company.\nImage source: Getty Images.\nRoku: 408% implied sales growth by 2025\nTelevision streaming platform Roku (NASDAQ:ROKU) is yet another big-name stock on pace to more than quintuple sales in just five years. After bringing in $1.78 billion in full-year sales in 2020, Wall Street's consensus is calling for about $9.05 billion in revenue by 2025. That's an increase of 408%.\nRoku has two key catalysts in its sails. First, there's ongoing cord-cutting from consumers. Over a four-year stretch, the number of U.S. households with traditional cable, satellite, or telcoTV services has fallen by more than 21 million to 75.6 million, according to a report from NScreenMedia.com. Meanwhile, the number of households without these traditional services now stands at more than 50 million. The opportunity to provide these households with streaming content of their choosing, be it free or paid content, is clearly helping Roku win over customers (55.1 million active accounts, as of June 2021).\nBut the more exciting opportunity for Roku is with programmatic digital ads. As consumers shift their viewing content from traditional cable and satellite to streaming providers, advertisers are responding by putting more of their budget to work with companies like Roku. More active accounts will give Roku increased ad pricing power, which in turn will it allow it grow its average revenue per user (ARPU) at a rapid clip. In the June-ended quarter, ARPU grew by 46%, even though active accounts increased by only 28% year over year.\nImage source: Getty Images.\nModerna: 1,605% implied sales growth by 2025\nHowever, the king of the mountain, at least on this list, is biotech stock Moderna (NASDAQ:MRNA). Sales for Moderna are expected to grow from a reported $803.4 million in 2020 to an estimated $13.7 billion by 2025. That's an increase of more than 1,600%!\nWhile it's not uncommon to see rapid nominal sales growth when clinical-stage biotech stocks introduce their first drug for sale, Moderna's launch from minimal revenue to multiple billions occurred quickly, thanks to its development of a COVID-19 vaccine, mRNA-1273. In clinical studies, mRNA-1273 led to a 94% vaccine efficacy and demonstrably helped inoculated patients stay out of the hospital with severe forms of the illness.\nFrom a business standpoint, Moderna continues to benefit from the need to inoculate billions of people worldwide, as well as the mutability of the SARS-CoV-2 virus that causes COVID-19. The need for booster shots or annual vaccines could give Moderna a source of recurring revenue.\nOn the other hand, the vaccine space is growing more crowded, with a number of new entrants expected within the U.S. and globally. Considering that mRNA-1273 is the company's only revenue-generating drug, Moderna's $126 billion market cap can best be described as precarious.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1032,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829164011,"gmtCreate":1633481487949,"gmtModify":1633481488214,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Dead cat rebound&nbsp;","listText":"Dead cat rebound&nbsp;","text":"Dead cat rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829164011","repostId":"1101968131","repostType":4,"repost":{"id":"1101968131","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1633473672,"share":"https://www.laohu8.com/m/news/1101968131?lang=&edition=full","pubTime":"2021-10-06 06:41","market":"us","language":"en","title":"Wall Street closes sharply higher as Big Tech roars back","url":"https://stock-news.laohu8.com/highlight/detail?id=1101968131","media":"Reuters","summary":"Oct 5  - Wall Street ended sharply higher on Tuesday, as Microsoft and Apple spearheaded a strong rebound in growth stocks and investors awaited monthly payrolls data later this week that could influence the U.S. Federal Reserve's decision on when to scale back monetary stimulus.Apple, Microsoft, Amazon and Alphabet, Wall Street's most valuable companies, each rose more than 1% following a selloff in growth stocks the day before.Facebook Inc rebounded 2.1% a day after taking a beating when its a","content":"<ul>\n <li>Facebook bounces as services resume following outage</li>\n <li>Tech and financials among top advancers</li>\n <li>PepsiCo gains on raising annual revenue forecast</li>\n <li>Indexes: Dow +0.92%, S&amp;P 500 +1.05%, Nasdaq +1.25%</li>\n</ul>\n<p>Oct 5 (Reuters) - Wall Street ended sharply higher on Tuesday, as Microsoft and Apple spearheaded a strong rebound in growth stocks and investors awaited monthly payrolls data later this week that could influence the U.S. Federal Reserve's decision on when to scale back monetary stimulus.</p>\n<p>Apple, Microsoft, Amazon&nbsp;and Alphabet, Wall Street's most valuable companies, each rose more than 1% following a selloff in growth stocks the day before.</p>\n<p>Facebook Inc&nbsp;rebounded 2.1% a day after taking a beating when its app and its photo-sharing platform Instagram went offline for hours.</p>\n<p>Nine of the 11 major S&amp;P 500 sector indexes rose, with financials, communication services&nbsp;and technology&nbsp;leading the way.</p>\n<p>The S&amp;P 500 logged its fourth straight day of 1% moves in either direction. The last time the index saw that much volatility was in November 2020, when it rose or fell 1% or more for seven straight sessions.</p>\n<p>\"We're buying the dip, but the dip isn't 10% anymore. The dip is now 2%, or 4%,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"People are trained like Pavlov's dog to buy the dip, which is reinforcing all of this.\"</p>\n<p>Technology stocks and other high-growth stocks took a beating on Monday as U.S. Treasury yields ticked higher amid concerns about a potential U.S. government debt default.</p>\n<p>The Senate will vote on Wednesday on a Democratic-backed measure to suspend the U.S. debt ceiling, a key lawmaker said on Tuesday, as partisan brinkmanship in Congress risks an economically crippling federal credit default.</p>\n<p>Investors will watch September employment data on Friday for hints about the tapering of the U.S. Federal Reserve's asset purchase program.</p>\n<p>Adding to concerns the Fed could tighten monetary policy sooner than expected, recent data showed increased consumer spending, accelerated factory activity and elevated inflation.</p>\n<p>Data from the Institute for Supply Management showed its U.S. non-manufacturing activity index edged up to a reading of 61.9 last month from 61.7 in August.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.92% to end at 34,314.67 points, while the S&amp;P 500&nbsp;gained 1.05% to 4,345.72.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.25% to 14,433.83.</p>\n<p>The S&amp;P 500 is down more than 3% from its record high close on Sept. 2. However, about half of the index's components have fallen 10% or more from their own 52-week highs.</p>\n<p>PepsiCo Inc&nbsp;gained 0.6% after raising its full-year revenue forecast.</p>\n<p>Volume on U.S. exchanges was 10.3 billion shares, compared with the 10.9 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.45-to-1 ratio; on Nasdaq, a 1.43-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 16 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 71 new highs and 207 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street closes sharply higher as Big Tech roars back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street closes sharply higher as Big Tech roars back\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-06 06:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Facebook bounces as services resume following outage</li>\n <li>Tech and financials among top advancers</li>\n <li>PepsiCo gains on raising annual revenue forecast</li>\n <li>Indexes: Dow +0.92%, S&amp;P 500 +1.05%, Nasdaq +1.25%</li>\n</ul>\n<p>Oct 5 (Reuters) - Wall Street ended sharply higher on Tuesday, as Microsoft and Apple spearheaded a strong rebound in growth stocks and investors awaited monthly payrolls data later this week that could influence the U.S. Federal Reserve's decision on when to scale back monetary stimulus.</p>\n<p>Apple, Microsoft, Amazon&nbsp;and Alphabet, Wall Street's most valuable companies, each rose more than 1% following a selloff in growth stocks the day before.</p>\n<p>Facebook Inc&nbsp;rebounded 2.1% a day after taking a beating when its app and its photo-sharing platform Instagram went offline for hours.</p>\n<p>Nine of the 11 major S&amp;P 500 sector indexes rose, with financials, communication services&nbsp;and technology&nbsp;leading the way.</p>\n<p>The S&amp;P 500 logged its fourth straight day of 1% moves in either direction. The last time the index saw that much volatility was in November 2020, when it rose or fell 1% or more for seven straight sessions.</p>\n<p>\"We're buying the dip, but the dip isn't 10% anymore. The dip is now 2%, or 4%,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"People are trained like Pavlov's dog to buy the dip, which is reinforcing all of this.\"</p>\n<p>Technology stocks and other high-growth stocks took a beating on Monday as U.S. Treasury yields ticked higher amid concerns about a potential U.S. government debt default.</p>\n<p>The Senate will vote on Wednesday on a Democratic-backed measure to suspend the U.S. debt ceiling, a key lawmaker said on Tuesday, as partisan brinkmanship in Congress risks an economically crippling federal credit default.</p>\n<p>Investors will watch September employment data on Friday for hints about the tapering of the U.S. Federal Reserve's asset purchase program.</p>\n<p>Adding to concerns the Fed could tighten monetary policy sooner than expected, recent data showed increased consumer spending, accelerated factory activity and elevated inflation.</p>\n<p>Data from the Institute for Supply Management showed its U.S. non-manufacturing activity index edged up to a reading of 61.9 last month from 61.7 in August.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.92% to end at 34,314.67 points, while the S&amp;P 500&nbsp;gained 1.05% to 4,345.72.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.25% to 14,433.83.</p>\n<p>The S&amp;P 500 is down more than 3% from its record high close on Sept. 2. However, about half of the index's components have fallen 10% or more from their own 52-week highs.</p>\n<p>PepsiCo Inc&nbsp;gained 0.6% after raising its full-year revenue forecast.</p>\n<p>Volume on U.S. exchanges was 10.3 billion shares, compared with the 10.9 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.45-to-1 ratio; on Nasdaq, a 1.43-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 16 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 71 new highs and 207 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101968131","content_text":"Facebook bounces as services resume following outage\nTech and financials among top advancers\nPepsiCo gains on raising annual revenue forecast\nIndexes: Dow +0.92%, S&P 500 +1.05%, Nasdaq +1.25%\n\nOct 5 (Reuters) - Wall Street ended sharply higher on Tuesday, as Microsoft and Apple spearheaded a strong rebound in growth stocks and investors awaited monthly payrolls data later this week that could influence the U.S. Federal Reserve's decision on when to scale back monetary stimulus.\nApple, Microsoft, Amazon and Alphabet, Wall Street's most valuable companies, each rose more than 1% following a selloff in growth stocks the day before.\nFacebook Inc rebounded 2.1% a day after taking a beating when its app and its photo-sharing platform Instagram went offline for hours.\nNine of the 11 major S&P 500 sector indexes rose, with financials, communication services and technology leading the way.\nThe S&P 500 logged its fourth straight day of 1% moves in either direction. The last time the index saw that much volatility was in November 2020, when it rose or fell 1% or more for seven straight sessions.\n\"We're buying the dip, but the dip isn't 10% anymore. The dip is now 2%, or 4%,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"People are trained like Pavlov's dog to buy the dip, which is reinforcing all of this.\"\nTechnology stocks and other high-growth stocks took a beating on Monday as U.S. Treasury yields ticked higher amid concerns about a potential U.S. government debt default.\nThe Senate will vote on Wednesday on a Democratic-backed measure to suspend the U.S. debt ceiling, a key lawmaker said on Tuesday, as partisan brinkmanship in Congress risks an economically crippling federal credit default.\nInvestors will watch September employment data on Friday for hints about the tapering of the U.S. Federal Reserve's asset purchase program.\nAdding to concerns the Fed could tighten monetary policy sooner than expected, recent data showed increased consumer spending, accelerated factory activity and elevated inflation.\nData from the Institute for Supply Management showed its U.S. non-manufacturing activity index edged up to a reading of 61.9 last month from 61.7 in August.\nThe Dow Jones Industrial Average rose 0.92% to end at 34,314.67 points, while the S&P 500 gained 1.05% to 4,345.72.\nThe Nasdaq Composite climbed 1.25% to 14,433.83.\nThe S&P 500 is down more than 3% from its record high close on Sept. 2. However, about half of the index's components have fallen 10% or more from their own 52-week highs.\nPepsiCo Inc gained 0.6% after raising its full-year revenue forecast.\nVolume on U.S. exchanges was 10.3 billion shares, compared with the 10.9 billion average over the last 20 trading days.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.45-to-1 ratio; on Nasdaq, a 1.43-to-1 ratio favored advancers.\nThe S&P 500 posted 16 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 71 new highs and 207 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889183816,"gmtCreate":1631114512235,"gmtModify":1631889326757,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","listText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","text":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889183816","repostId":"1180788041","repostType":4,"isVote":1,"tweetType":1,"viewCount":36,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":698891874,"gmtCreate":1640331386141,"gmtModify":1640331634599,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"It's always the up and down&nbsp;","listText":"It's always the up and down&nbsp;","text":"It's always the up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698891874","repostId":"2193078140","repostType":4,"repost":{"id":"2193078140","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299360,"share":"https://www.laohu8.com/m/news/2193078140?lang=&edition=full","pubTime":"2021-12-24 06:42","market":"us","language":"en","title":"S&P 500 hits record close as Omicron fears ebb","url":"https://stock-news.laohu8.com/highlight/detail?id=2193078140","media":"Reuters","summary":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* ","content":"<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 hits record close as Omicron fears ebb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 hits record close as Omicron fears ebb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Major indexes climb for 3rd straight session</p>\n<p>* Merck's at-home COVID-19 pill gets U.S. approval</p>\n<p>* Weekly jobless claims unchanged at 205,000</p>\n<p>* Consumer spending increases 0.6% in November</p>\n<p>* Indexes up: Dow 0.55%, S&amp;P 0.62%, Nasdaq 0.85%</p>\n<p>Dec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&amp;P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.</p>\n<p>Stocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&amp;P 500 sectors, led by consumer discretionary&nbsp;and industrials, which both rose about 1.2%.</p>\n<p>Vaccine makers <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>&nbsp;and Novavax Inc&nbsp;said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.</p>\n<p>The arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.</p>\n<p>“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 196.67 points, or 0.55%, to 35,950.56, the S&amp;P 500&nbsp;gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite&nbsp;added 131.48 points, or 0.85%, to 15,653.37.</p>\n<p>Defensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector&nbsp;fell 0.4%.</p>\n<p>The S&amp;P 500 has gained for three days, after falling in the three prior sessions.</p>\n<p>“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.</p>\n<p>For the week, the S&amp;P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.</p>\n<p>Trading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.</p>\n<p>In another medical development against the pandemic, the United States authorized Merck &amp; Co's&nbsp;antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.</p>\n<p>The number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.</p>\n<p>Tesla Inc&nbsp;shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.</p>\n<p>The S&amp;P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.</p>\n<p>About 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193078140","content_text":"* Major indexes climb for 3rd straight session\n* Merck's at-home COVID-19 pill gets U.S. approval\n* Weekly jobless claims unchanged at 205,000\n* Consumer spending increases 0.6% in November\n* Indexes up: Dow 0.55%, S&P 0.62%, Nasdaq 0.85%\nDec 23 (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&P 500 marking a record-high close, as encouraging developments gave investors more ease about the economic impact of the Omicron coronavirus variant.\nStocks ended the holiday-shortened week on a positive note, lifting sentiment heading into Christmas. Gains were broad among S&P 500 sectors, led by consumer discretionary and industrials, which both rose about 1.2%.\nVaccine makers AstraZeneca Plc and Novavax Inc said their shots protected against Omicron as UK data suggested it may cause proportionally fewer hospital cases than the Delta variant, though public health experts warned the battle against COVID-19 was far from over.\nThe arrival of Omicron has helped ratchet up market volatility for much of the last month of 2021, which has been a strong year for equities.\n“There was a lot of negative sentiment coming into the final part of the year, and investors have likely continued to see pretty strong economic growth and pretty positive developments as it relates to healthcare innovation around COVID and that is putting in a bit of a bid into equities and causing investors to look to allocate capital as they close out the year,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\nThe Dow Jones Industrial Average rose 196.67 points, or 0.55%, to 35,950.56, the S&P 500 gained 29.23 points, or 0.62%, to 4,725.79 and the Nasdaq Composite added 131.48 points, or 0.85%, to 15,653.37.\nDefensive sectors, which have mostly outperformed in December, generally lagged on Thursday. The real estate sector fell 0.4%.\nThe S&P 500 has gained for three days, after falling in the three prior sessions.\n“People are seeing the strength on Tuesday and Wednesday and all of a sudden everybody is more optimistic again,” said Robert Pavlik, senior portfolio manager at Dakota Wealth Management.\nFor the week, the S&P 500 rose 2.3%, the Dow gained about 1.7% and the Nasdaq climbed 3.2%.\nTrading volumes were expected to be thinner than usual ahead of the Christmas and New Year holidays. The stock market will be closed on Friday in observance of the Christmas holiday.\nIn another medical development against the pandemic, the United States authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc. Merck shares fell 0.6%, while Pfizer dropped 1.4%.\nThe number of Americans filing new claims for unemployment benefits held below pre-pandemic levels last week as the labor market tightens, while consumer spending increased solidly, putting the economy on track for a strong finish to 2021.\nTesla Inc shares rose 5.8%, gaining sharply for a second day after Chief Executive Elon Musk said on Wednesday he was \"almost done\" with his stock sales after selling over $15 billion worth since early November.\nThe S&P 500 is up about 26% so far this year. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.40-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored advancers.\nThe S&P 500 posted 35 new 52-week highs and no new lows; the Nasdaq Composite recorded 62 new highs and 80 new lows.\nAbout 8 billion shares changed hands in U.S. exchanges, compared with the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":837841920,"gmtCreate":1629878190660,"gmtModify":1631889326785,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Just nice for a good meal&nbsp;[开心]&nbsp;","listText":"Just nice for a good meal&nbsp;[开心]&nbsp;","text":"Just nice for a good meal [开心]","images":[{"img":"https://static.tigerbbs.com/61f1d66c1649a52a5d1d63e3a4b16cb7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837841920","isVote":1,"tweetType":1,"viewCount":306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":630619131,"gmtCreate":1642812029157,"gmtModify":1642812029359,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Cathy will be gone soon&nbsp;","listText":"Cathy will be gone soon&nbsp;","text":"Cathy will be gone soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/630619131","repostId":"1116834406","repostType":4,"isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693469990,"gmtCreate":1640063725361,"gmtModify":1640064058108,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Should start positioning at 86. 70 is too bearish&nbsp;","listText":"Should start positioning at 86. 70 is too bearish&nbsp;","text":"Should start positioning at 86. 70 is too bearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693469990","repostId":"1180317442","repostType":4,"repost":{"id":"1180317442","pubTimestamp":1640057402,"share":"https://www.laohu8.com/m/news/1180317442?lang=&edition=full","pubTime":"2021-12-21 11:30","market":"us","language":"en","title":"Let the Roblox Share Price Decline to $70, Then Start a Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1180317442","media":"InvestorPlace","summary":"After a meteoric rise, hot metaverse bet RBLX stock just needs to cool down","content":"<p>California-based online entertainment platform&nbsp;<b>Roblox</b>&nbsp;(NYSE:<b><u>RBLX</u></b>) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the red-hot metaverse space, RBLX stock has generated major buzz on Wall Street.</p>\n<p>Indeed, as the term “metaverse” gained traction in the financial news headlines, Roblox share price soared. However, as the old saying goes, trees don’t grow straight to the heavens.</p>\n<p>In other words, even white-hot RBLX stock couldn’t just keep going up forever. All it took was a worse-than-expected user-growth update, and Roblox was suddenly out of favor with investors.</p>\n<p>It’s funny how the tide of sentiment can turn so quickly. Contrarians who still believe in the future of metaverse-anchored gaming can take advantage of the market’s overreaction as Roblox’s news has not been all bad.</p>\n<p><b>A Closer Look at RBLX Stock</b></p>\n<p>Just to recap, RBLX stock&nbsp;debuted on March 10&nbsp;of this year. Interestingly enough, the shares became publicly traded through the&nbsp;very first direct listing of 2021.</p>\n<p>The stock actually began trading at $64.50 and finished its first day of trading at $69.50. Then its upward momentum accelerated as its price ramped up to a 52-week high of $141.60 in November.</p>\n<p>Unfortunately, this moon shot wasn’t sustainable. RBLX stock fell quickly in November’s back half and continued declining in December, falling as low as $95 and change.</p>\n<p>Experts often recommend avoiding buying sharply falling stocks in order to refrain from “catching a falling knife.”</p>\n<p>Roblox has fairly solid support at $70, so it’s not a terrible idea to be patient and let its share price hit that critical price point before taking a position in the name.</p>\n<p><b>A Subtle Bug</b></p>\n<p>Some may assume that RBLX stock simply fell victim to gravity after flying too far, too fast.</p>\n<p>Yet this wasn’t just an instance of Icarus flying too close to the sun. Rather, there were specific incidents that popped the shares’ bubble.</p>\n<p>The first of these incidents took place in late October and early November, when Roblox reportedly experienced a three-day&nbsp;outage during the Halloween weekend.</p>\n<p>This was a period in which the company would typically take in at least $15 million in revenue. So&nbsp; that three-day outage was a big deal for Roblox. Just as painfully, RBLX stock lost more than $1.5 billion worth of its market capitalization as a result of this incident.</p>\n<p>Of course, Roblox CEO David Baszucki had some ” ‘splaining” to do. He claimed that the outage had been “especially difficult” as it involved a “combination of several factors.”</p>\n<p>“A core system in our infrastructure became overwhelmed, prompted by a subtle bug in our backend service communications while under heavy load… This was not due to any peak in external traffic or any particular experience,” Baszucki explained.</p>\n<p><b>A Possible Overreaction</b></p>\n<p>Evidently, Roblox’s investors weren’t too impressed with the CEO’s account or at least Baszucki’s explanation didn’t prevent many investors from unloading all of their RBLX stock.</p>\n<p>Fast-forward to mid-December, and Roblox released its&nbsp;usage statistics&nbsp;for the month of November. Investors reacted very negatively to the data, and they may have overreacted.</p>\n<p>Roblox counted 49.4 million average daily active users in November, up 35% year-over-year. That sounds pretty good, if you ask me.</p>\n<p>On the other hand, that figure was less than the 50.5 million average daily active users Roblox reported for the first 27 days of October.</p>\n<p>That’s not a huge decline. And in November, Roblox generated estimated bookings of between $208 million and $211 million, up 22% to 24% YOY.</p>\n<p>On top of all that, Roblox reported 3.6 billion hours engaged in November, representing a 32% YOY gain.</p>\n<p><b>The Bottom Line</b></p>\n<p>It’s not always easy to tread the line between optimism and caution.</p>\n<p>Yet that’s the right approach to RBLX stock, given the investing community’s negative sentiment towards Roblox at the moment. Thus, it’s wise to let the share price continue on its likely path to $70 and then re-evaluate and take a long position in the name if you’re ready to do so.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Let the Roblox Share Price Decline to $70, Then Start a Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLet the Roblox Share Price Decline to $70, Then Start a Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>California-based online entertainment platform Roblox (NYSE:RBLX) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the ...</p>\n\n<a href=\"https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"source_url":"https://investorplace.com/2021/12/let-the-roblox-share-price-decline-to-70-then-start-a-position/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180317442","content_text":"California-based online entertainment platform Roblox (NYSE:RBLX) empowers people to play video games and socialize in a vast, 3D, virtual world. Since the company was an early-stage entrant in the red-hot metaverse space, RBLX stock has generated major buzz on Wall Street.\nIndeed, as the term “metaverse” gained traction in the financial news headlines, Roblox share price soared. However, as the old saying goes, trees don’t grow straight to the heavens.\nIn other words, even white-hot RBLX stock couldn’t just keep going up forever. All it took was a worse-than-expected user-growth update, and Roblox was suddenly out of favor with investors.\nIt’s funny how the tide of sentiment can turn so quickly. Contrarians who still believe in the future of metaverse-anchored gaming can take advantage of the market’s overreaction as Roblox’s news has not been all bad.\nA Closer Look at RBLX Stock\nJust to recap, RBLX stock debuted on March 10 of this year. Interestingly enough, the shares became publicly traded through the very first direct listing of 2021.\nThe stock actually began trading at $64.50 and finished its first day of trading at $69.50. Then its upward momentum accelerated as its price ramped up to a 52-week high of $141.60 in November.\nUnfortunately, this moon shot wasn’t sustainable. RBLX stock fell quickly in November’s back half and continued declining in December, falling as low as $95 and change.\nExperts often recommend avoiding buying sharply falling stocks in order to refrain from “catching a falling knife.”\nRoblox has fairly solid support at $70, so it’s not a terrible idea to be patient and let its share price hit that critical price point before taking a position in the name.\nA Subtle Bug\nSome may assume that RBLX stock simply fell victim to gravity after flying too far, too fast.\nYet this wasn’t just an instance of Icarus flying too close to the sun. Rather, there were specific incidents that popped the shares’ bubble.\nThe first of these incidents took place in late October and early November, when Roblox reportedly experienced a three-day outage during the Halloween weekend.\nThis was a period in which the company would typically take in at least $15 million in revenue. So  that three-day outage was a big deal for Roblox. Just as painfully, RBLX stock lost more than $1.5 billion worth of its market capitalization as a result of this incident.\nOf course, Roblox CEO David Baszucki had some ” ‘splaining” to do. He claimed that the outage had been “especially difficult” as it involved a “combination of several factors.”\n“A core system in our infrastructure became overwhelmed, prompted by a subtle bug in our backend service communications while under heavy load… This was not due to any peak in external traffic or any particular experience,” Baszucki explained.\nA Possible Overreaction\nEvidently, Roblox’s investors weren’t too impressed with the CEO’s account or at least Baszucki’s explanation didn’t prevent many investors from unloading all of their RBLX stock.\nFast-forward to mid-December, and Roblox released its usage statistics for the month of November. Investors reacted very negatively to the data, and they may have overreacted.\nRoblox counted 49.4 million average daily active users in November, up 35% year-over-year. That sounds pretty good, if you ask me.\nOn the other hand, that figure was less than the 50.5 million average daily active users Roblox reported for the first 27 days of October.\nThat’s not a huge decline. And in November, Roblox generated estimated bookings of between $208 million and $211 million, up 22% to 24% YOY.\nOn top of all that, Roblox reported 3.6 billion hours engaged in November, representing a 32% YOY gain.\nThe Bottom Line\nIt’s not always easy to tread the line between optimism and caution.\nYet that’s the right approach to RBLX stock, given the investing community’s negative sentiment towards Roblox at the moment. Thus, it’s wise to let the share price continue on its likely path to $70 and then re-evaluate and take a long position in the name if you’re ready to do so.","news_type":1},"isVote":1,"tweetType":1,"viewCount":809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827789810,"gmtCreate":1634523506698,"gmtModify":1634523506960,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Buy. No regrets&nbsp;","listText":"Buy. No regrets&nbsp;","text":"Buy. No regrets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827789810","repostId":"1195761146","repostType":4,"isVote":1,"tweetType":1,"viewCount":807,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829159740,"gmtCreate":1633482174945,"gmtModify":1633482175191,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still a falling knife&nbsp;","listText":"Still a falling knife&nbsp;","text":"Still a falling knife","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829159740","repostId":"2173911317","repostType":4,"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864460267,"gmtCreate":1633139179949,"gmtModify":1633139635194,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","listText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","text":"Will report at the hell. Not worth trading [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864460267","repostId":"2172968387","repostType":4,"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889432961,"gmtCreate":1631167227953,"gmtModify":1631884166336,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","text":"$GameStop(GME)$Aviod, more downside to come.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889432961","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}